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ABSTRACT 
 Periodontal disease is initiated by bacterial plaque that induces a chronic inflammatory 
condition with subsequent leukocyte infiltration, osteoclast activation and alveolar bone 
resorption. The ideal treatment for periodontal disease is the complete regeneration of the lost 
periodontium. Resolvin E1 (RvE1) is an endogenous anti-inflammatory lipid mediator derived 
from omega-3 fatty acids. Animal studies showed that topical treatment of periodontitis with RvE1 
significantly decreased osteoclast counts, prevented alveolar bone loss, and restored lost 
periodontal tissues including bone. It is not known if RvE1 directly impacts osteoblast functions 
and bone formation. The objective of this study was to determine RvE1 mechanism of action on 
osteoblasts. Results showed that topical RvE1 treatment prevented the progression of ligature-
induced periodontitis in mice compared to the vehicle. RvE1 receptor, chemR23, was expressed 
in murine calvaria osteoblasts and the expression was not changed in the inflammatory 
environment with or without RvE1 treatment.  RvE1 treatment resulted in a significant increase in 
the ALP activity after 2 and 7 days of treatment compared to the control as well as in the 
inflammatory milieu. Similarly, RvE1 treatment enhanced murine calvaria osteoblasts 
mineralization in vitro compared to the inflammatory environment. The proliferation of mouse 
calvaria osteoblasts was significantly increased with RvE1 treatment after 2 and 10 days of 
treatment compared to the control. Results for evaluating the impact of RvE1 on OPG/RANKL 
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axis showed that RvE1 treatment markedly elevated OPG production compared to the IL-6/IL-6R 
treatment and decreased RANKL. Overall, RvE1 increased the OPG/RANKL ratio to favor bone 
formation. RvE1 treatment resulted in a significant increase in the phosphorylation of AKT, 
ERK1/2 and ribosomal S6 (rS6) kinase. Those pathways were further confirmed via using specific 
pharmacological inhibitors which showed a significant reduction in OPG production and in the 
osteoblast proliferation as well. In conclusion, RvE1 has a positive anabolic impact in ligature-
induced periodontitis model via direct actions on osteoblasts. RvE1 increases the OPG/RANKL 
production ratio favoring the bone formation through a pathway that includes phosphorylation of 
AKT, ERK1/2 and rS6 kinase. The data suggest that RvE1 stimulates bone formation in 
inflammatory conditions by directly modulating both the osteoclast and osteoblast functions. 
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1. Introduction and review of literature 
1.1 Inflammation 
 Inflammation is a response to a variety of injuries or infections. By definition, it is “a 
complex reaction to injurious agents such as microbes and damaged, usually necrotic, cells that 
consists of vascular responses, migration and activation of leukocytes, and systemic reactions”.1,2 
It was first described by the Roman, Cornelius Celsus, in the 1st century, who defined the cardinal 
signs of inflammation: rubor et tumor cum calore et dolore (redness and swelling with heat and 
pain).1,3,4 Later, Rudolph Virchow's added a fifth sign of inflammation that is functio laesa (loss 
of function) after investigating the cellular basis of pathology.  
Robert Koch and Louis Pasteur proposed that microorganisms are major inducers of the 
acute inflammation.3 Acute inflammation is considered to be a physiological response to defend 
the host and maintain homeostasis. Acute inflammation is characterized by rapid onset, short 
duration, fluid exudation and migration of leukocytes, primarily neutrophils. If the injury persists, 
chronic inflammation is established, which can be considered as pathologic. It is characterized by 
a longer duration, lymphocyte and macrophage infiltration, blood vessel proliferation, and fibrosis. 
As a result, adaptive immune response will be activated with all of the cellular and non-cellular 
mechanisms of acquired immunity. Thus, coordination of inflammatory and immune responses is 
very important to restore homeostasis to the injured tissues.1,5–12  
Inflammatory response is characterized by vasodilation, increased permeability of 
capillaries, increased blood flow and leukocyte recruitment. The function of inflammation is to 
eliminate the injurious agent while initiating processes for healing and restoration homeostasis of 
the damaged tissues. Inflammatory response consists of vascular and cellular reactions that play 
interactive roles at various stages of the process. Involved cells include circulating cells such as 
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neutrophils, monocytes, eosinophils, lymphocytes, basophils, and platelets; cells surrounding 
blood vessels which are mast cells, and resident cells such as fibroblasts and macrophages.1 As the 
first line of defense of the innate immunity due to their phagocytic ability, neutrophils are the first 
cells to migrate along chemotaxis gradient and accumulate in inflamed tissues. Then, monocytes 
and macrophages follow neutrophils to clear cellular debris and apoptotic neutrophils by 
phagocytosis without prolonging inflammation; a nonphlogistic process.1,3,5,11,13–17 Preventing this 
cell recruitment is one of the strategies to reduce inflammation in inflammatory-mediated 
diseases.14,17 Failure to clear apoptotic neutrophils and inflammatory cells via phagocytosis 
characterize the chronic and pathological lesion. This failure could be involved in the pathogenesis 
of inflammatory diseases such as arthritis, cardiovascular diseases and periodontal diseases.1,3,18,19 
Studying of the inflammatory response was limited to evaluating proinflammatory cytokines. 
However, it was discovered that there are mediators that follow the proinflammatory cytokines 
that result in resolution of inflammation (Figure 1).3 
 Proinflammatory lipid mediators, the eicosanoids, are involved in host defense and 
inflammation.1,3,5,6,11,12,20–22 Arachidonic acid is a precursor of eicosanoids and it is derived from 
cell-membrane phospholipids via phospholipase A2. Arachidonic acid can be converted to a 
variety of lipid mediators through the action of cyclooxygenases, lipoxygenases or epoxygenases 
to produce prostaglandins, leukotrienes and endoperoxides, respectively (Figure 2).3,5,6,10–12 
Prostaglandin E2 (PGE2) is generated in leukocytes via prostaglandin E synthase, while 
prostaglandin I2 is generated in endothelial cells via prostacyclin synthase and thromboxanes are 
generated in platelets via thromboxane synthase.3,21,23 Leukotrienes can be produced by 
polymorphonuclear leukocytes, macrophages and mast cells. Excessive production of 
prostaglandins and leukotrienes in response to inflammatory inducers is associated with 
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progression from acute inflammation to chronic inflammation in many diseases. They are 
considered as autacoids within the innate acute inflammatory response. Currently, blocking 
prostaglandin synthesis can be achieved with the use of nonsteroidal anti-inflammatory drugs 
(NSAID) such as aspirin and cyclooxygenase inhibitors. Although they are effective in clinical 
treatment, there is considerable controversy regarding their general safety and side effects in the 
gastrointestinal and cardiovascular systems as well as about their cost.1,7,15,24–29 Favorable 
inflammatory processes are self-limiting, which indicates the presence of an endogenous 
inflammation resolution pathway.3,6 
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Figure 1: Outcomes of acute inflammation 
 
 
Figure 1: An illustration of the fate of acute inflammation. Microbial infection, tissue injury or 
tissue stress may induce the release of chemical mediators, such as leukotriene B4 and 
prostaglandin E2. The outcome of acute inflammation; resolution or chronicity and fibrosis 
depends on the class of lipid mediators and the persistence of the injury. Chronic inflammation 
can result from excessive and/or unresolved inflammatory responses and can lead to chronic 
disorders. Proinflammatory lipid mediators such as prostaglandins and leukotrienes can amplify 
this process. As a result, fibrosis can occur when inflammatory injury causes substantial tissue 
destruction, connective tissue replacement occurs and results in loss of tissue function. The 
resolution and return to normal homeostasis is an actively regulated program at the tissue level via 
switching of arachidonic-acid-derived lipids from LTB4 production to lipoxin A4 production with 
subsequent production of anti-inflammatory and proresolving lipid mediators (Adapted from 
reference 12). 
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1.2 Resolution of inflammation 
Resolution of inflammation is a highly coordinated and active process in which leukocytes 
and removed and resident cells return to a homeostasis state.3,5,10,11,15,16,30,42-47 This process is as 
complex as the inflammatory process. It involves restoration of chronically inflamed tissues with 
severe matrix destruction, fibrosis and impaired wound healing to health.19,35 During the resolution 
phase of inflammation, cells and mediators provide ‘stop signals’ that lead to the clearance of 
inflammatory cells.15,19,37 Pro-resolving mediators are generated in tissues and limit inflammatory 
cells recruitment toward the inflamed site, reverse the cardinal signs of inflammation (such as 
vasodilatation and vascular permeability) and coordinate the clearance of leukocytes, exudates and 
fibrin, eventually leading to the restoration of homeostasis (Figure 2).19,38 These pro-resolving 
mediators limit tissue injury and prevent progression of acute inflammation into chronic status. If 
tissue damage is significant, healing will be in form of scar formation where fibrin is not cleared 
efficiently, and granulation tissue is formed.2,7,15,19 Failure to resolve inflammation in periodontitis 
leads to scar formation and failure to regenerate lost periodontium.19  
 In periodontal diseases, inflammatory cell infiltrate, matrix degradation and alveolar bone 
loss is caused by the release of certain lipid mediators such as prostaglandins, thromboxanes and 
leukotrienes.9,35,39 During the resolution of inflammation, a ‘class switch’ occurs within 
neutrophils, leading to the synthesis of proresolving mediators through pathways different from 
the pro-inflammatory pathways. Proresolving mediators include lipoxins, resolvins, maresins and 
protectins, which are critical mediators of inflammation resolution that act through a number of 
complex intracellular processes. These mediators lead to inhibiting neutrophil recruitment to the 
inflammatory site, attracting monocytes that do not release proinflammatory mediators, enhancing 
phagocytosis of bacteria and apoptotic cells by macrophages, directing the movement of 
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phagocytes away from the site via the lymphatics and stimulating the synthesis of antimicrobial 
agents3,9,19,30,34,51–54 This approach was already showed promising results. In a periodontitis model 
in animals, results showed that by resolution of inflammation, periodontal tissues were regenerated 
and there was a significant restoration of the subgingival microflora to one consistent with health 
without the use of any antimicrobials agent.8,35,45 This indicates the potential ability of resolvins to 
induce antimicrobial activities in resolving mucosal inflammation.35,40 
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Figure 2: Pro-inflammatory and pro-resolving lipid mediators 
 
 
Figure 2: Lipid mediators are involved in initiation of acute inflammation and resolution which 
restores tissue homeostasis. Arachidonic acid –derived eicosanoids such as prostaglandin E2 and 
thromboxane A2 are pro-inflammatory mediators. Pro-resolving lipid mediators include 
arachidonic acid-derived lipoxin A4, EPA-derived E-series resolvins, and DHA-derived D-series 
resolvins, protectins, and maresins. COX: cyclooxygenase, LO: lipoxygenase. (Adapted from 
reference 7).  
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1.3 Resolvin E1 (RvE1) 
 Several in vitro46–49  and in vivo46,50–59 studies showed that polyunsaturated fatty acids 
(PUFAs) have been implicated in bone homeostasis. Evidence indicated that lack of certain PUFAs 
in the diet can induce bone loss46,60–62, whereas dietary supplementation of some PUFAs has been 
shown to be beneficial for bones.46,52,53,63,64,7465 For example, clinical studies have shown that 
supplementation of calcium, γ-linolenic acid and eicosapentaenoic acid (EPA) in the diets 
increased bone mineral density and reduced bone turnover in elderly women.46,63,64 In vivo studies 
have shown that, in ovariectomized animals, PUFAs such as γ-linolenic acid, EPA and 
docosahexaenoic acid (DHA) supplementation could prevent bone resorption.46,49,52 Additionally, 
in rheumatoid arthritis patients, clinical trials showed that ω-3 (PUFAs) reduced joint stiffness in 
the morning and the number of tender joints, decreased the levels of inflammatory cytokines in the 
blood, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-
6).66–71 Similarly, intravenous administration of ω-3 fatty acids leads to clinical improvements in 
patients with rheumatoid arthritis.16,58 Others reports demonstrate the potential benefits of dietary 
supplementation with ω-3 fatty acids. For instance, in healthy subjects, ω-3 fatty acids reduce 
lipopolysaccharide (LPS)-induced fever and inflammatory responses.16,59 Also, in hypertensive 
postmenopausal females, soy nuts, enriched with ω-3 fatty acids, improve systolic blood pressure 
and low-density lipoprotein cholesterol levels.16,51 Moreover, in children at risk of type 1 diabetes, 
ω-3 fatty acids reduce risk.16,72  
Resolvins are endogenous lipid mediators that are produced during the resolution phase of 
inflammation. They are biosynthesized from the ω-3 polyunsaturated fatty acids EPA and DHA 
derived from the diet.3,30,44,73 They are generated through a pathway via cell-cell interactions and 
transcellular biosynthesis during inflammation or microbial challenges. In the presence of aspirin, 
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RvE1 can be generated through two different pathways. One is via a pathway that involves cells 
containing cyclooxygenase-2 that has been acetylated by aspirin treatment and cells that possess 
5-lipoxygenase (5-LO). Another pathway is aspirin-independent and the microbial cytochrome 
P450 monooxygenase can contribute to RvE1 production in vivo.3,14,32,43,74 Aspirin-modified 
cyclooxygenase-2 converts EPA to 18-R-hydroperoxyeicoapentaenoic acid and 18-S-
hydroperoxyeicoapentaenoic acid in vascular endothelium. Those intermediates will be taken up 
by neutrophils where they are metabolized to RvE1 (RvE1:5S,12R,18R-trihydroxy-
6Z,8E,10E,14Z,16E-eicosapentaenoic acid) by 5-LO (Figure 3).5,8,10,11,41,42 Aspirin and EPA 
supplements increase the production of RvE1 in the plasma which results in improving clinical 
signs of inflammation.3,31,75–77 Originally RvE1 was discovered in vivo in exudates from murine 
dorsal pouches after aspirin and EPA treatment during resolution phase of inflammation, and was 
generated during coincubation of human endothelial cells and neutrophils.74,78 These newly 
produced resolvins may be responsible for some of the beneficial effects of taking ω-3 EPA that 
are enhanced with aspirin therapy.33,42,56,74,78–80 Dietary supplementation with ω-3 PUFAs indicates 
that they have positive impact in certain inflammatory-mediated diseases such as cardiovascular 
disease, arthritis, Alzheimer’s disease, asthma, and periodontitis, peritonitis and 
pneumonia.21,56,66,74,81 
Chemokine-like receptor 1 (also known as ChemR23) is a receptor for RvE1. It is one of 
the G protein-coupled receptors (GPCRs). ChemR23 is expressed on monocytes and dendritic 
cells. Moreover, chemR23 was found to be expressed in a variety of tissues, including 
cardiovascular system, brain, kidney, lung, gastrointestinal tissues, salivary glands and myeloid 
tissues. Additionally, a murine receptor counterpart was found in developing bone using in situ 
hybridization. ChemR23 is also expressed in bone marrow stromal cells and osteoblasts.31,82,83 
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whereas osteoclasts express the BLT1 receptor.31,65 RvE1 receptor, ChemR23, was identified from 
a panel of GPCRs using a counter regulatory screening system.14,17,74,84,85 Another receptor for 
resolvins is BLT1, a leukotriene B(4) (LTB(4)) receptor, which is expressed on neutrophils.3,33,44,74 
Binding of RvE1 to its receptors attenuates nuclear factor-kappa B (NF-ĸB) signaling and the 
production of pro-inflammatory cytokines, including TNF-α.3,33,74 Also, RvE1 has been shown to 
enhance cell migration in corneal epithelial cells which was associated with phosphorylation of 
the epidermal growth factor receptor (EGFR) and downstream signaling involving 
phosphatidylinositol 3-kinase (PI3K) and p38.86 
ChemR23 can bind another ligand, chemerin.14,87 Chemerin has been found at high levels 
in psoriatic skin, arthritic joints and in ascetic fluids from human ovarian and liver cancers.14,17,88,89 
Under physiological conditions, chemerin circulates as a prochemerin, an inactive form. It can be 
activated via the proteolytic removal of amino acids at the C-terminal end by proteases of the 
coagulation, fibrinolytic and inflammatory cascades.14,90 Also, neutrophils can convert 
prochemerin to chemerin which suggests that the chemerin/ChemR23 signaling system could serve 
as a bridge between innate and adaptive immunity.14,91 
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Figure 3: RvE1 biosynthesis 
 
Figure 3: RvE1 can be synthesized through aspirin dependent or aspirin independent pathways. 
Aspirin acetylate endothelial cyclooxygenase-2 (COX-2) or microbial cytochrome P450 
monooxygenase to convert EPA to 18-R-hydroperoxyeicoapentaenoic acid (18R-HEPE). When 
endothelial cells interact with leukocytes during acute inflammation, 5-lipooxygenase converts 
18R-HEPE to 5,6-epoxy,18R-HEPE and eventually to RvE1: 5S,12R,18R-trihydroxy-
6Z,8E,10E,14Z,16E-eicosapentaenoic acid (Adapted from reference 92).    
 
 
 
 
12 
 
There are several targets for RvE1 anti-inflammatory actions. One of them is polymorph 
nuclear leukocytes (PMNs) in which RvE1 reduces their transendothelial migration and release of 
superoxide generation.33,78,92 Same actions have been evident in vivo, where RvE1 blocks PMN 
infiltration in peritonitis and colitis.33,74,80 Also, RvE1 reduces antigen presenting functions via 
attenuation of dendritic cell migration and interleukin -12 (IL-12) production via ChemR23.33,74 
The relation between resolution and infection is of interest because of the known side effects of 
anti-inflammatory drugs on the immune system.11,93 As an impact on infections, topical RvE1 
clears P. gingivalis which reduces severity of periodontal disease in rabbits.8,94 Also, infections 
with Herpes simplex virus in the eye lead to stromal keratitis with viral-initiated 
immunopathology. Topical treatment with RvE1 in this infectious mouse model, reduced pro-
inflammatory mediators by stimulating interleukin-10 (IL-10).11,95,96 Additionally, beneficial 
impact of RvE1 in Candida infections was found where it enhances yeast killing and clearance in 
mice.11,97 These finding indicate that treating the host during infection with these pro-resolving 
mediators could aid in reducing inflammation and enhancing infection clearance.11,77,98,99 
Moreover, epithelial and microvascular injury can lead to excessive fibrosis when there is failure 
of inflammation resolution. Treatment with RvE1 was found to protect from renal fibrosis by 
reducing collagen I and IV, α-smooth muscle actin (α-SMA) and fibronectin.11,100 In the context 
of regeneration after trauma or infection, resolution of inflammation may provide a pivotal role in 
that regard. Exogenous RvE1 stimulates dermal wound healing, reduces neutrophilic infiltration 
and stimulates reepithelialization of murine skin wounds.11 Also, RvE1 reduces tissue regeneration 
times.11,101 In lymphoid tissues, exogenous RvE1 upregulates chemokine receptor type 5 (CCR5) 
expression on leukocytes that bind chemokines, facilitating their clearance and resolution. In 
addition, RvE1 induces apoptosis of activated T cells via 2,3-dioxygenase induction in dendritic 
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cells (DC) and it reduces mouse CD4+ T cells and CD8+ T cells in atopic dermatitis (Table 
1).11,102,103 
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Table 1: RvE1 impact on multiple cell types 
Cells RvE1 actions(s) 
Neutrophils 
Inhibits transepithelial and transendothelial migration.12  
Blocks fMLP-stimulated superoxide production in localized aggressive 
periodontitis.92 
Macrophages 
Stimulates non-phlogistic phagocytosis of apoptotic neutrophils.12 
Increases MAPK activation in monocytes.74 
Reduces the number of macrophages that ingest apoptotic PMN.104 
Increases clearance of macrophages from inflammation areas.105 
Dendritic cells 
Increases apoptosis of activated T cells.102 
Blocks IL-12 production.12 
T-cells Up-regulates CCR5 expression.106 
Platelets Blocks platelet aggregation.43 
Corneal epithelium Increases cell migration.107 
Mucosal epithelial 
cells 
Increases CD55 expression, increases apical clearance of PMN40  
Increases alkaline phosphatase expression and activity of bacterial 
detoxification in the intestine.108 
Adipocytes 
Increases adiponectin in adipose tissue collected from ob/ob mice ex 
vivo.109 
Myocytes Preventive treatment with RvE1 reduced infarct size.110 
Osteoclasts 
Inhibits osteoclasts differentiation, proliferation, reduces the resorption 
pit formation and TRAP activity.8,31,65 
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Signaling properties of RvE1 showed that it increases phosphorylation of extracellular 
signal regulated kinase (ERK), mitogen-activated protein (MAP) kinase in monocytes and Gαi/o 
activation in human embryonic kidney (HEK)-overexpressing ChemR23 cells. Treatment of HEK-
ChemR23 cells with pertussis toxin (PTX) abolished RvE1-dependent ERK activation and nuclear 
factor-kappa B (NF-ĸB) inhibition, suggesting coupling to Gαi/o protein for the signal 
transduction.74,86 Other reports indicate that RvE1 activates chemR23 and induces receptor-
dependent phosphorylation.111 In human ChemR23-transfected Chinese hamster ovary cells 
(CHO), RvE1 regulated phosphorylation of AKT in a time and dose-dependent manner. Also, 
RvE1 induced phosphorylation of ribosomal protein S6, a translational regulator. RvE1-induced 
phosphorylation was inhibited by a PI3K inhibitor (wortmannin) and an ERK inhibitor (PD98059). 
Similarly, in ChemR23-expressing differentiated HL60 cells, RvE1 stimulated the 
phosphorylation of ribosomal protein S6.111  
Animal models for periodontitis were utilized to evaluate the role of resolution mediators 
in disease prevention. For example, topical application of RvE1 improved signs of disease activity, 
reduced bone loss, decreased the number of neutrophils. Also, leukocyte infiltration was reduced 
when RvE1 was used in a mouse dorsal air pouch model.3,112 Similarly, RvE1 and lipoxin A4 
reduced superoxide production from neutrophils in response to TNF-α and the bacterial N-
formylmethionyl-leucyl-phenylalanine (fMLP), by 80% in human cells from patients with 
localized aggressive periodontitis.3,43 RvE1’s bone-protective action was demonstrated in 
periodontal bone loss in vivo.10,31,92 Periodontitis was induced in rabbits by silk ligature and 
inoculation of P. gingivalis to the second mandibular premolar. Topical application of RvE1 (4 
mg) was done three times per week for 6 weeks and alveolar bone loss was evaluated. Radiological 
and morphometric analyses showed that RvE1 treatment significantly inhibited alveolar bone loss. 
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Histological analysis demonstrated that RvE1 treatment reduced the number of tartrate-resistant 
acid phosphatase (TRAP)-positive osteoclasts around the alveolar bone. Gingival inflammation 
was also reduced with RvE1 treatment. In the same model, a direct comparison of the actions of 
RvE1, PGE2 and LTB4 was performed.8,31 Results showed that PGE2 and LTB4 worsened 
alveolar bone loss, while RvE1 treatment resulted in a complete true periodontal tissue 
regeneration, including regeneration of alveolar bone, periodontal ligament and cementum. 
Results from in vivo studies demonstrate the potential of RvE1 impact in prevention of 
periodontitis. Another study evaluated the temporal dynamics of inflammation-induced dysbiosis 
of the periodontal microbiota.45 Periodontitis was induced in rats using ligatures to observe 
changes in the microbiota and the host without the addition of exogenous pathogens. Differential 
gene expression in periodontal tissues was evaluated in health, disease and after treatment with 
RvE1. Topical RvE1 treatment resulted in prevention of bone loss in ligature induced periodontitis, 
reduction of osteoclast density and inflammatory cell infiltration, and reduction in the expression 
of inflammation-related genes returning the expression profile to one more similar to health. In 
addition, RvE1 treatment of established periodontitis reversed bone loss, reversed inflammatory 
gene expression and reduced osteoclast density. In terms of subgingival microflora, RvE1 
treatment resulted in marked changes in both prevention and treatment experiments. These results 
demonstrate that modulation of local inflammation has a major role in shaping the composition of 
the subgingival microbiota. However, the question remained about the actual mechanism of RvE1 
in those models. Does RvE1 act directly on bone cells or indirectly through inhibiting 
proinflammatory mediators?  
In vitro studies using murine primary osteoclasts showed that RvE1 indeed directly acts on 
osteoclasts. RvE1 treatment decreased the number and size of differentiated osteoclasts induced 
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by macrophage colony-stimulating factor (MCSF) and receptor activator of nuclear factor kappa-
Β ligand (RANKL).31,65 RvE1 decreased resorption pit formation, an action mediated through 
BLT1 receptor on osteoclasts. Evaluation of the cellular mechanism of RvE1’s impact on 
osteoclasts showed that RvE1 downregulated the expression of the osteoclast fusion protein 
dendritic cell–specific transmembrane protein (DC-STAMP), due to defective binding of the 
osteoclast-specific transcription factor nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) 
to the DC-STAMP promoter.31,65,113 However, according to results from in vivo studies, RvE1 
impact should be exerted on both osteoclasts and osteoblasts to promote bone formation and inhibit 
bone resorption. One study evaluated RvE1’s impact on osteoblasts. In a craniotomy defect study, 
RvE1 (100 ng) was injected subcutaneously over the craniotomy defect every other day for 2 
weeks. RvE1 markedly accelerated the healing rate of the defect.31,82 In vitro evaluation of RvE1 
impact on osteoblast cultures showed that RvE1 rescued osteoprotegerin (OPG) expression 
suppressed by proinflammatory mediators, thus decreasing the RANKL/OPG ratio and favoring 
bone formation.31,82 These findings indicate that RvE1 acts directly on osteoblasts by regulating 
the RANKL/OPG ratio. The potential for treatment of periodontal diseases with one or a 
combination of specialized lipid mediators is clear and requires further investigation. 
 
1.4 Bone metabolism 
Bone provides the body with the required protection for vital organs, an attachment site for 
muscles and tendons, calcium source for various cellular processes, and hematopoietic cells in its 
marrow. Bone is a dynamic biological system with different processes, such as bone growth and 
development, continuous bone remodeling, maintenance of serum calcium, and pathological 
conditions which include osteoporosis, inflammatory bone diseases, and bone tumors. About 10% 
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of the total bone mass in the body is renewed yearly, constituting a major source of calcium and 
phosphate mineral homeostasis for maintaining the skeletal integrity and physiological 
functions.66,114 Bone metabolism is under the control of systemic hormonal regulators which are 
regulated by serum calcium levels such as parathyroid hormone and calcitonin, and other local 
regulators such as PGE2, cytokines, 1,25-dihydroxyvitamin D3, corticosteroids, estrogens, 
transforming growth factors, and bone morphogenic proteins.31,46,115–121 
 
1.5 Osteoblasts 
Osteoblasts are differentiated from pluripotent stromal cells. Their differentiation is 
controlled by several factors which contribute to the development and maintenance of the 
osteoblast phenotype and the mineralization process (Figure 4). Those factors include, bone 
morphogenetic proteins (BMPs), glucocorticoids and other steroid hormones, and the extracellular 
matrix (ECM).121–126 Additionally, specific transcription factors are required for the expression of 
bone-related genes, osteoblast-specific factor 2 (Osf2) which is the bone-specific product of the 
Cbfa1 gene and locus of the cleidocranial dysplasia.122,127–129 Runt-related transcription factor 2 
(Runx2) is an essential factor for bone development. It is an early marker of osteoblast 
differentiation. Runx2 regulates the differentiation of pre-osteoblasts into osteoblast lineage. 
Previous reports showed that skeletal development in Runx2 knockout animals did not proceed 
beyond the cartilage anlage stage.127,129,130 Factors that modulate the expression of Runx2 are bone 
BMPs, CBF-p 35, SMAD proteins, SOX9, TWIST, histone deacetylases or histone deacetylases 
accessory factors.131–135 Additionally, Runx2 activity is controlled by transcriptional modification. 
Activation of MAPK pathway by  integrins results in phosphorylation and stimulation of Runx2 
transcriptional activity.133 Other genes that are required for the ECM production contain binding 
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sites for Runx2. Moreover, Runx2 regulates the expression of other osteoblast markers such as 
osteocalcin (Ocn) and type I collagen. Thus, stimulating calcification of the ECM.136 However, it 
was reported that the amount of Runx2 bound to the target genes remains relatively unchanged 
during differentiation.137 Proinflammatory cytokines such as TNF suppress osteoblast maturation 
in vitro by inhibiting the expression of Runx-2, type I collagen (Col1a1), alkaline phosphatase 
(Alp), and Ocn. Thus, bone matrix deposition and mineralization are thus impaired by TNF. Also, 
IL-1β elicits similar inhibitory responses in differentiating osteoblasts.138–142  
Another transcription factor that is involved in early osteoblast differentiation is osterix 
(Osx).143 Osx expression in Runx2-expressing cells induces their differentiation into mature 
osteoblasts.130,144–149 Previous studies demonstrated that Osx-null embryos did not express 
osteoblast markers, although the expression of Runx2 was normal. Also, the expression of Col1a1 
was significantly reduced in Osx mutants. Among the latest markers of osteoblasts, bone 
sialoprotein (Bsp) and Ocn, were absent in Osx-null embryos. It was found that Osx was not 
expressed in skeletal parts of Runx2-null embryos, which indicate that Runx2 is an upstream 
regulator of Osx and that Osx triggers Runx2-expressing cells to differentiate into osteoblasts by 
activating expression of osteoblasts genes.130,146,148,150 
Moreover, other several molecules have been linked with the mineralization process, such 
as bone phosphoproteins. Members of this group are BSP, Osteopontin (OPN), and bone acidic 
glycoprotein-75. Previous in vivo reports showed that all three proteins may accumulate in 
mineralized structures and bind hydroxyapatite (HA). However, only BSP showed a highly tissue-
specific distribution to mineralized tissues and an expression pattern that was closely associated 
with early mineralization.122,151–155 Similarly, in vitro studies showed that BSP is a potent initiator 
of mineral formation.122,156–159 Nevertheless, in vitro mineralization is very different from 
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mineralization in bone, in vivo, where HA crystals are deposited in between the collagen fibrils in 
a complex ECM. That’s why it is recommended to study the mineralization process in 
experimental conditions that could mimic the bone environment, in vivo. Primary osteoblast 
cultures can serve that requirement for optimal conditions for experiments that mimic the bone 
environment.116,122,160–162  
Typical sources of primary osteoblasts can be: (1) neonatal calvaria cells via collagenase 
digestion of rat or mouse calvaria bones, (2) bone marrow-derived mesenchymal stromal cells 
(BMSCs), or (3) cells migrating from trabecular bone explants.120,163 These culture models have 
distinct phases of proliferation and differentiation. After plating, primary osteoblasts enter a 
proliferative phase in which synthesis of collagenous ECM starts. Once matrix synthesis is 
initiated, specific osteoblast marker genes will be activated in a distinct sequence. At early stages, 
ALP and the parathyroid hormone (PTH)/parathyroid hormone-related protein (PTHrP) receptor 
are induced, whereas at later stages, BSP and OCN will be expressed.122,124,163–165 Collagenous 
ECM synthesis is required for induction of osteoblast differentiation markers. As a result, ascorbic 
acid (AA) acts as a cofactor for collagen synthesis and is required for osteoblast differentiation in 
vitro and in vivo.122,124,125,166,167 AA stimulates hydroxylation of proline and lysine residues in 
collagen, its processing, and fibril assembly, followed by induction of OCN, ALP, BSP, and PTH 
receptor. Several reports showed that low AA intakes reduced bone mass, increased the rate of 
bone loss, and fractures.120,168–170 In vivo studies suggest that AA deficiency induces increased 
bone resorption due to an increased oxidative stress causing increased osteoclast number and 
activity along with proliferation of dysplastic immature osteoblasts.171 During a second maturation 
phase occurring in week 2 or 3, matrix mineralization is observed.122,163,172–175 The mineral phase 
in primary osteoblast cultures is a deposition of calcium-phosphate, substituted hydroxyapatite that 
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is seen in mineralized tissues, such as bone, cartilage and teeth.163,176 In vitro mineralization is only 
initiated when the media is further supplemented with 5–10 mM β-glycerol phosphate (β-
GP).120,122,163,173 It is worth mentioning that several factors can influence cell behavior in vitro. For 
example, the medium, its additives used for cell culturing, and the seeding density. Monolayer cell 
culture are the standard method for maintaining osteoblast cells in vitro. However, this does not 
reflect natural physiological conditions. That’s why establishing a cell system that mimics the 
physiological environment of cells should of more interest.120  
Osteoblasts regulate mineralization of the extracellular matrix by precise expression of 
multiple factors. Mineralization occurs by deposition of crystals into collagen fibers.114,117,177 
There are various theories explaining the mineralization process, the most likely being 
heterogeneous nucleation. It involves apposition of organic or inorganic particles that direct the 
formation of apatite from soluble inorganic ions. One theory proposed that calcium and phosphate 
are transported into matrix vesicles which initiate nucleation, as a prerequisite to subsequent 
mineralization.178–180 Inside the vesicles, the ions interact with phospholipids to form nucleation 
complexes and nanocrystals.180–183 Other theories proposed a direct nucleation of apatite by matrix 
macromolecules, especially collagen, and supported by phosphoproteins, phospholipids, and 
proteolipids.184–187 Additionally, Runx2 triggers the expression of ALP, which extracts phosphate 
from the extracellular matrix or from external substrates such as β-GP. In osteoblast precursor cell 
line derived from mouse calvaria (MC3T3), ALP activity was observed 3 days after AA and β-GP 
stimulation, and continued to increase for up to 24 days.124 Evaluation of ALP mRNA in AA-
stimulated cultures supplemented or not with BGP was found and peaked at day 16 of stimulation 
with AA. Collagen synthesis inhibitors inhibited ALP mRNA expression, as well as its enzymatic 
activity.124 ALP activity in rat calvaria osteoblasts is followed by expression of OCN.161 In another 
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study, the activity of ALP from the cytoplasmic fraction of MC3T3 cells peaked at 10 days and 
decreased thereafter to less than half the maximum level.188 Osteoid mineralization occurs when 
phosphate and calcium combine to form crystals of impure HA in the matrix vesicles.189–191 Then, 
osteoblasts secrete those vesicles and deposit mineral crystals on the osteoid.190–192  
Osteocalcin is a small, highly conserved acidic protein that regulates mineral maturation 
and bone resorption.193–195 OCN mRNA can be detected 10 days after the differentiation with AA 
in MC3T3 cells. At a later stage, between days 16 and 28, OCN mRNA levels are correlated with 
formation of bone nodules.188 BSP is one of the major phosphoproteins in bone which is expressed 
by osteoblasts. In addition to being highly phosphorylated, this protein is glycosylated and was 
found to be implicated in HA binding. The expression of BSP is upregulated by factors that 
stimulate bone formation. It has multiple roles in bone remodeling and its expression is restricted 
to mineralized tissues. It is thought to initialize mineral crystal formation in vitro196  and in vivo.197 
High levels of BSP protein in mineralizing clones of MC3T3 were found to be correlated to mRNA 
expression.122 BSP induces HA nucleation in vitro and differentiation of pre-osteoblasts.158,198 
Factors that may enhance ECM mineralization by osteoblasts in vitro include: culture media199,200, 
cell density199,201, the duration of culture time202, and supplementing media with organic 
phosphates.116,203,204 
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Figure 4: Differentiation of osteoblasts 
 
Figure 4: Differentiation of osteoblasts. Mesenchymal progenitor cells will be committed toward 
the osteoblast lineage via signaling by Wnt/ β-catenin pathway such as BMPs which induces the 
osteogenic transcription factors Runx2 and osterix. Differentiation to the mature osteoblast that 
actively mineralizes bone matrix is dependent on the transcription factor osterix. Matrix maturation 
is associated with increased expression of alkaline phosphatase and noncollagenous proteins, 
including osteocalcin and bone sialoprotein. Mineralization of bone is completed by the 
incorporation of hydroxyapatite into the newly deposited osteoid. Membrane-bound extracellular 
matrix vesicles released from the osteoblast facilitate initial mineral deposition by accumulating 
calcium and phosphate ions. At the completion of bone formation, a subset of osteoblasts can be 
entrapped in the bone matrix and become osteocytes. The remaining osteoblasts are thought to 
either undergo apoptosis or become inactive bone-lining cells (Adapted from reference 205). 
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1.6 OPG/RANKL ratio is critical for bone remodeling 
The ability of bone to adapt to growth and changes in physical activities and mechanical 
loads is remarkable. For example, tooth loss with subsequent absence in biting forces leads to a 
severe alveolar bone resorption.31,115 Continuous bone remodeling is achieved via the interaction 
between osteoclasts which resorb bone and osteoblasts which form new bone matrix that is 
subsequently mineralized.31,66,115,205 Entrapped osteoblasts in the newly formed bone become 
osteocytes which connect to each other and also with osteoblasts at the surface via distinct dendritic 
processes through a canalicular system in the bone. Osteocytes are considered mechanosensing 
cells that can detect mechanical strain and initiate signaling pathways, promoting both 
osteoclastogenesis and osteoblastogenesis.31,114,205 Another possible function of osteocytes is that 
bone microdamage induces osteocyte apoptosis which may plays a role in skeletal 
remodeling.114,206 It was thought that factors secreted from osteoblasts and bone marrow stromal 
cells control the differentiation and formation of osteoclasts, till the discovery of 
RANKL/RANKL/OPG, members of the tumor necrosis factor superfamily.66,114,207,208 Based on 
three independent research groups in 1997–1998, it is now believed that RANKL ⁄ RANK ⁄ OPG 
regulate bone remodeling, differentiation and formation of osteoclasts and their precursors.114,209–
213  
Osteoclastogenesis is regulated by RANKL, its receptor, RANK, and a decoy receptor, 
OPG.46 RANKL is a type II homotrimeric transmembrane protein expressed both as a membrane-
bound and a secreted protein.118 Factors that stimulate osteoclast formation and activity stimulate 
RANKL expression in osteoblasts and stromal cells. RANKL is expressed in lymph nodes, 
thymus, and lung and is expressed at low levels in a variety of other tissues, including spleen and 
bone marrow. In inflamed joints of rheumatoid arthritis patients, RANKL is expressed by synovial 
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cells and is secreted by activated T cells which could be the reason for joint destruction in those 
patients.46,118 The release of osteoclast precursors into the circulation is stimulated by RANKL. 
Also, RANKL is expressed by some malignant tumor cells, which also express RANK and thus 
could have a role in inducing tumor cell proliferation.118 Binding of RANKL to its receptor on pre-
osteoclasts activates c-jun terminal kinase and NF-ĸB which leads to their fusion and 
differentiation into mature osteoclasts, osteoclastogenesis and inhibits osteoclast apoptosis. 
RANKL-knockout mice display an osteopetrotic phenotype due to the absence of osteoclasts. After 
administration of RANKL to these animals, osteoclast formation and function was restored with 
subsequent enhancement of bone resorption and the development of osteoporosis.35,66,115,118 
RANKL along with PGE2 can stimulate osteoclast differentiation and initiate bone 
remodeling.31,115,205 Under healthy conditions, RANKL in the periodontal tissues is expressed by 
osteoblasts and PDL cells.115 RANKL expression is important in term of adaptation to occlusal 
forces, during tooth eruption, or during orthodontic tooth movement.115,214–216 In periodontal 
diseases, RANKL’s main source is Th1 or Th17 cells, as well as B-cells115,217–220, although resident 
mesenchymal cells may also express RANKL under bacterial challenge.115,221,222 Interestingly, T-
regulatory cells can attenuate RANKL expression by other activated T-cells.115  
RANK is a type I homotrimeric transmembrane protein, which is expressed widely in 
normal cells and in some cancer cells, including breast and prostate cancers which have high risk 
for bone metastasis. RANK mutations in humans result in an increase in RANK-mediated NF-ĸB 
signaling as well as an increase in osteoclast formation and activity. Those mutations may explain 
the increased osteolysis in Paget’s disease.118  
On the other hand, OPG, a soluble tumor necrosis factor receptor-like molecule which acts 
as a decoy and blocks the binding of RANKL to RANK and thus prevents osteoclastogenesis. OPG 
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is expressed in many tissues including osteoblasts, spleen, bone marrow, heart, liver, and kidney. 
Factors that induce RANKL expression by osteoblasts can regulate OPG expression.118 Various 
mediators modulate OPG secretion which may be stimulated by estrogen, phytoestrogens, IL-1β 
and  Transforming growth factor-β (TGF-β), but is inhibited by interleukin-1α (IL-1α), PGE2, 
PTH, glucocorticoids and vitamin A metabolites.46 RANKL/OPG ratio is considered the main 
factor to determine bone mass in different clinical conditions, although there are contradictory 
data.118 Moreover, bone mass may be influenced directly by Wnt/β-catenin signaling in 
osteoblasts. This signaling pathway regulates differentiation of mesenchymal cells to the 
osteoblast lineage and the amount of bone laid down by osteoblasts. An observation showed that 
Wnt/β-catenin signaling directly regulates OPG expression by osteoblastic cells.118,121 Based on 
the findings of several reports, two major signaling pathways—OPG/RANKL/RANK in 
osteoclasts and Wnt/β-catenin in osteoblasts—could have a pivotal role in determining bone mass. 
Osteoblasts are involved in both pathways.46,118,121 Proinflammatory cytokines may disrupt the 
Wnt signaling pathway. Regulation of Wnt signaling is maintained by a number of secreted 
antagonists, including members of the secreted frizzled-related protein (sFRP) and Dickkopf 
(DKK) families.138 
In the healthy periodontium, OPG is continually produced by resident periodontal 
connective tissue fibroblasts and potentially endothelial cells121, but not epithelial cells, or T-
cells.115,218,221 In periodontitis, OPG production is produced by the same cells as in health. OPG 
knockout mice showed an osteoporotic phenotype.35,115,211 Whereas mice overexpressing OPG 
expressed osteopetrotic phenotype due to the lack of osteoclast formation and a lack of bone 
resorption.35,118 Osteocytes apoptosis due to bone stress may induce RANKL expression from 
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neighboring osteoblasts. Therefore, the bone remodeling is initiated: bone resorption by osteoclasts 
is followed by bone matrix deposition by osteoblasts.  
 
1.7 Inflammatory diseases of bone 
The imbalance between bone resorption and bone formation plays a pivotal role in a variety 
of systemic conditions such as osteoporosis, hyperparathyroidism, rheumatoid arthritis, and 
periodontitis. For example, in rheumatoid arthritis plasma cells, macrophages, and T cells 
accumulate in the synovial membrane of affected joints and produce RANKL which induces 
osteoclast differentiation and survival, leading to subchondral bone resorption in the joint 
surfaces.31,115,205,221 Additionally, T cells express proinflammatory cytokines such as TNF-α and 
IL-1 with subsequent expression of RANKL in osteoblasts and bone marrow stromal cells which 
in turn can activate osteoclasts and induce bone resorption. Proinflammatory cytokines such as 
TNF-α, IL-1, IL-6, IL-11, and IL-17 play an important but indirect role in osteoclast regulation 
through modulating RANKL and OPG. They can act on osteoblasts and bone marrow stromal cells 
to increase RANKL/OPG ratio by increasing RANKL and reducing OPG expression. Also, 
prostaglandins and TGF-β may act on osteoblasts through RANKL/OPG mediation. On the other 
hand, anti-inflammatory cytokines such as IL-4, IL-10, and interferon-γ act on osteoblasts in an 
opposite fashion to inhibit bone resorption via decreasing RANKL or increasing OPG. Thus, the 
RANKL/OPG plays a significant role in controlling osteoclast differentiation and is the main 
molecular factor in regulating bone resorption or formation.31,66,115,205 
Another example of inflammatory bone resorption is periodontitis. It is a bacterially 
induced inflammation leads to the disease of the jaw. It is considered a public health problem 
worldwide, including the United States where it is affecting approximately one-half of the adult 
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population.31,98 Periodontal diseases impact the dentition as well as the systemic health.19,35. For 
instance, one-third of diabetic patients show signs of severe periodontitis, and patients with severe 
periodontitis show increased risk of poor glycemic control, increasing the risk of oral and systemic 
complications. Hyperglycemia may impact neutrophils and monocytes through various 
mechanisms, including the accumulation of advanced glycation end products, which results in an 
increase production and release of superoxide as well as pro-inflammatory cytokines, such as IL-
1β, TNF-α, and matrix metalloproteinases (MMPs).3 Due to the failure of resolution, periodontitis 
leads to prolonged activation of neutrophils and monocytes with ineffective clearance of bacteria, 
which may worsens systemic diabetes status. Also, periodontitis was shown to be a risk indicator 
for cardiovascular disease in cross-sectional and cohort studies.3 The link between periodontitis 
and cardiovascular diseases could be due to the presence of elevated cytokines and markers of 
inflammation, including C-reactive protein (CRP), fibrinogen, IL-1β, IL-6, TNF-α and PGE2. 
They are produced in the inflamed gingival tissues and maybe secreted into the circulation and 
have systemic impact, such as induction of endothelial dysfunction.20,223,224 By controlling the 
progression of periodontitis, the levels of those inflammatory markers are decreased, which, in 
turn, may decrease the severity of cardiovascular diseases. After adjusting for risk factors, such as 
smoking, diabetes, alcohol intake, obesity and blood pressure, subjects with periodontitis had a 
1.14- to 1.59-fold greater risk of developing cardiovascular diseases compared with those without 
periodontitis.3,225 
The periodontal diseases could be in a mild form, gingivitis, or a chronic and aggressive 
forms of periodontitis. All forms of periodontal diseases are characterized by chronic inflammation 
which results in destruction of the periodontal ligament and bone. If left untreated, severe bone 
loss occurs with subsequent tooth mobility and tooth loss. If bacterial plaque biofilm is not 
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disrupted and removed, chronic inflammation of periodontal tissues will be established which 
leads to release of inflammatory cytokines, leading to gingival soft tissue destruction. The initial 
response in periodontitis, acute inflammation, is considered to be a physiologic response to the 
bacterial challenge.  It helps to recruit required cells to the location of infection via the release of 
cytokines and chemokines. Failure to resolve the infection leads to the initiation of the chronic 
lesion. As a result, phagocytosis of microorganisms and foreign substances by macrophages and 
neutrophils with the aid of surface receptors that recognize and bind bacteria will occur.8,9,23,58,98 
After recognition of microorganisms, cytokines and chemokines are secreted to attract phagocytes. 
Also, the complement system is activated to generate active proteins, such as the anaphylotoxins 
C3a, C4a and C5a to attract host immune cells, including monocytes, lymphocytes and neutrophils. 
There is variability in the clinical manifestation and the rate of disease progression in periodontitis. 
This variability could be due to variability of the subgingival microbial flora. Another explanation 
of the variability is the variability of inflammatory response of the host which leads to the tissue 
destruction. Thus, bacteria are necessary for initiation of periodontitis, however, disease 
progression is due to an inflammatory response within a susceptible host.9,35 One of the main 
features of periodontitis is the increased osteoclast activity without a concomitant enhancement in 
bone formation by osteoblasts.226 Several animal and human periodontitis studies showed that 
osteoclasts resorb alveolar bone. Monocytes, macrophages, and T-cells release inflammatory 
cytokines in inflamed periodontal tissues which drive the formation of osteoclasts and bone loss 
follows. Understanding this process is fundamental in the ability to control the disease process. 
Similar to what is seen in rheumatoid arthritis, activated T cells express RANKL, leading to 
osteoclast activation and alveolar bone resorption.31,226 Several studies confirmed the impact of 
RANKL in periodontal bone loss. Elevated expression of RANKL has been noted in fibroblasts 
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and mononuclear cells in inflamed periodontal tissues which was closely associated with site of 
bone resorption.226 In periodontal tissues, OPG may be produced by periodontal ligament cells, 
gingival fibroblasts and epithelial cells and its expression is regulated by inflammatory 
cytokines.226 A few studies that evaluated the progression of periodontitis indicate that active 
periodontitis sites show higher RANKL tissue expression by 3.4- fold than inactive ones.115 These 
studies showed that attachment loss is associated with higher RANKL levels than disease 
remission. Other studies showed that OPG levels in the granulomatous tissue adjacent to alveolar 
bone loss is reduced. Thus, OPG/RANKL levels control the alveolar bone loss in 
periodontitis.115,226 
 
1.8 Treatment of periodontal diseases 
 In light of the above discussion about the pathogenesis of periodontitis, treatment strategies 
should not only be focused on reducing the bacterial load, rather, it should include controlling the 
inflammatory host response.7,35,43,227–230 Currently, periodontitis treatment focuses on control of 
the infection.35,45,229 It was previously believed that tooth loss as the only significant consequence 
of periodontitis. Once hopeless teeth were extracted, no further risk to the patient was assumed.19 
Thus, extensive teeth extractions were done as a ‘cure’ for ‘gum diseases’. Despite advancements 
in diagnosis and treatment, tooth extraction is still one of the most common dental procedures.19,231 
Also, treatment of periodontal diseases uses the same principles proposed by Pierre Fauchard in 
his 1746 publication, entitled ‘Le Chirurgien Dentiste’, and include scaling with instruments and 
use of mouthwashes and dentifrices.19,232 Although they are partially successful in removing the 
majority of microbial plaque, infection recurs and controlling the inflammatory response is 
difficult. The abnormal host inflammatory response in periodontitis could be due to a systemic 
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dysregulation of inflammation and therefore resolution of inflammation is not always possible 
using conventional treatment approaches.19,35,233,234 Moreover, if our goal is to have a full 
restoration of tissues to homeostasis, therefore, complete regeneration of the lost periodontium is 
also required. However, this is not the case in susceptible individuals with comorbidities such as 
diabetes or other inflammatory diseases. Complete and true periodontal regeneration is 
complicated and unpredictable.19,235 Thus, an accurate characterization of the mechanisms of the 
disease will help us to develop a new personalized treatment strategies targeting the susceptible 
individual rather than treating everyone with the same treatment regiment, regardless of the 
underlying cause.19  
 
1.9 The impact of IL-6 on bone in inflammation  
A major osteoclastogenesis pathway is RANKL-dependent which is known as canonical 
osteoclast formation. However, other cytokines may substitute RANKL to induce 
osteoclastogenesis such as TNF-α, IL-1, IL-6, and IL-11. These non-canonical osteoclastogenesis 
factors play a critical role in pathological bone resorption, however their underlying mechanisms 
remain unclear. The IL-6 family of cytokines includes IL-6, IL-11, leukemia inhibitory factor, 
oncostatin M, ciliary neurotrophic factor, cardiotrophin-1, cardiotrophin-2, cardiotrophin- like 
cytokine ⁄ novel neutrophin-1 ⁄ B-cell stimulatory factor-3, neuropoietin and interleukin-27.66,114 
Of these cytokines, IL-6, IL-11, leukemia inhibitory factor, oncostatin M, cardiotrophin-1 and IL-
27 have been found to be osteotropic. Their receptors dimerize with the signaling subunit 
glycoprotein 130 (gp130) and the functions therefore overlap, to some extent.114 IL-6 is a 
proinflammatory cytokine belonging to the gp130 family which share gp130 as a common signal 
transducer. Binding of IL-6 to its receptor, IL-6R, promotes homodimerization of gp-130, thereby 
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activating Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and the 
MAPK pathway.236–238 Soluble IL-6 receptor can be found in large amounts extracellularly. IL-6 
contains a signal domain which stimulates cells to release IL-6 in large amounts which can 
stimulate acute-phase response proteins in the liver and in the thermoregulatory center in the 
hypothalamus.114 Several reports showed that there are two distinct signaling pathways for IL-6, 
the classic (via the membrane-anchored IL-6R) and IL-6 transsignaling (via the soluble IL-6R 
(sIL-6R)). Gp130 is expressed in every cell type, whereas the IL-6R is predominantly expressed 
in hepatocytes, megakaryocytes and several leukocyte subpopulations. Evidence suggests that IL-
6 trans-signaling via the sIL-6R accounts for the proinflammatory properties of IL-6 (Figure 5).239 
Previous reports showed that IL-6 is involved in bone loss diseases, such as rheumatoid arthritis 
(RA), Paget’s disease, and multiple myeloma, in which enhanced IL-6 level occurs. Moreover, IL-
6 has been implicated in the pathogenesis of periodontitis by increasing MMPs.114,237,238,240 In 
periodontal tissues, IL-6 is expressed by osteoblasts, gingival fibroblasts and periodontal ligament 
cells, and its regulation is controlled by many cytokines and toll-like receptors.114 It has been 
shown that IL-6’s role in osteoclastogenesis requires assistance by sIL-6R, evidenced by the fact 
that IL-6 induces functional osteoclast formation only in the presence of sIL-6R, indicating 
insufficient expression of IL-6R, or maybe it cannot be activated because of the absence of a 
required transducer in osteoclastic lineage cells.236–238 It is believed that IL-6 stimulates 
osteoclastogenesis by indirectly increasing production of RANKL by osteoblasts, which in turn 
stimulates the commitment of osteoclast precursors into mature osteoclasts.236 Previous reports 
showed that IL-6 stimulates osteoclast formation in bone marrow cultures containing both stromal 
cells and hematopoietic cells as well as periosteal bone resorption in organ cultured mouse calvaria 
bone.114 Enhancement of RANKL production may be the mechanism by which the impact of IL-
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6 on bone resorption and osteoclast formation is regulated. Osteoblasts could to be the main target 
for the bone resorption impact of IL-6. In order to observe this impact in bone cell cultures, the 
addition of both IL-6 and sIL-6R is required.114  
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Figure 5: IL-6 signaling 
 
Figure 5: Scheme of IL-6 classic and trans-signaling. In classic signaling, IL-6 binds to its 
membrane-bound receptor (IL-6R), which then binds to a dimer of transmembrane glycoprotein 
130 (gp130), inducing anti-inflammatory signals. In trans-signaling, IL-6 binds to its soluble 
receptor (sIL-6R). The IL-6/sIL-6R complex then binds to the gp130 dimer, inducing pro-
inflammatory signals (Adapted from reference 236).  
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In light of the above discussion, pathogenesis of periodontitis involves inflammatory 
process which fails to resolve. Also, evidences from previous reports confirmed the positive 
impacts of RvE1in resolution of inflammation in a variety of inflammatory disease, including 
periodontitis. Several in vivo animal models showed that RvE1 treatment resulted in bone 
regeneration. Moreover, the impact of RvE1 on osteoclasts was explored extensively and showed 
positive outcomes in term of inhibiting osteoclasts differentiation, proliferation, and reducing the 
resorption pit formation6. However, bone remodeling is characterized by the coupling between 
bone formation with osteoblasts and bone resorption by osteoclasts. There is limited information 
regarding the direct action of RvE1 on osteoblasts in periodontal bone regeneration. We are trying 
to answer questions about the direct impact of RvE1 treatment on osteoblasts in an inflammatory 
milieu. Additionally, we are trying to dissect the mechanisms by which RvE1 exerts its action on 
osteoblasts. We aim to fill this gap in the knowledge about direct actions of RvE1 on bone in 
periodontal diseases. We anticipate that our results may aid to have a better understanding of the 
direct action of RvE1 on osteoblasts, which will explain the periodontal regeneration in vivo. 
Moreover, the results will demonstrate the potential of RvE1 as a pharmaceutical agent for 
regenerative treatment of periodontal disease with its impact on anabolic bone deposition.   
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2. Hypothesis 
RvE1 acts directly on osteoblasts via binding to a specific receptor, stimulating anabolic 
signaling pathways, promoting the osteoblast-mediated bone formation, and limiting osteoclast 
activity. It is expected that RvE1 will increase the OPG/RANKL ratio by inducing OPG production 
and decrease RANKL secretion by osteoblasts, which will limit the osteoclast formation.    
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3. Aims  
 
1. Determine Resolvin E1 action in ligature-induced periodontitis in mice. 
2. Determine the expression of the chemR23 in neonatal mouse calvaria osteoblasts. 
3. Determine the osteoblast function after RvE1 treatment.  
4. Determine the signaling pathway(s) for osteoblast responses to RvE1? 
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4. Methods 
4.1 Animals  
FVB mice were purchased from Jackson Laboratories (Bar Harbor, ME). All animals 
received standard chow diet and water ad libitum. All mouse experiments were approved by the 
Institutional Animal Care and Use Committee (IACUC) of the Forsyth Institute. 
 
4.2 Ligature-induced periodontitis  
Mice were anesthetized with Ketamine (100 mg/kg i.p.) and Xylazine (5 mg/kg, i.p.). A 7-
0 silk suture was placed into the gingival sulcus of the maxillary right and left second molars and 
tied around the tooth with the knot being placed on the palatal side. The animals were divided into 
three groups; control (No ligature), ligature + vehicle, and ligature+RvE1. Animals received 
topical treatment with 10 μM RvE1 or vehicle based on their group assignment daily for 7 days. 
One week later, mice were sacrificed and the maxillae were divided into right and left halves. The 
left half was defleshed, cleaned and stained with methylene blue (1% in water) for bone loss 
measurements. The alveolar area bound by the cementoenamel junction, the alveolar bone crest, 
mesial surface of the first molar, and the distal surface of the second molar was determined to 
assess alveolar bone loss using ImageJ software. 
 
4.3 Cell isolation and culture procedures  
Neonatal mouse calvaria osteoblasts were aseptically isolated from 3-day old litters by 
dissection of the scalp skin and removal of the calvaria. Frontal and parietal bones were stripped 
of periosteum and loosely adherent tissues. Calvaria were washed with a solution made of 137 mM 
NaCl, 2.7 mM KCl and 3 mM NaH2PO4 x H2O. Then, they were incubated for 10 minutes on a 
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shaker at 37°C in 4 mM Na2-EDTA solution, three times to demineralize the extracellular matrix. 
The supernatants were discarded. After that, they were incubated for 10 minutes twice at 37°C in 
a freshly prepared collagenase type 2 solution (Worthington) in 137 mM NaCl, 2.7 mM KCl, 3mM 
NaH2PO4 x H2O on a shaker to separate the cells from the extracellular matrix. The first two 
supernatants were discarded and the supernatants from the following five incubations were 
collected, pooled, centrifuged, and suspended in α-MEM media supplemented with 10% FBS, 
10,000 IU penicillin, and 10,000 μg/ml streptomycin. Cells were seeded into 75 ml flasks. At 90 
% confluence, cells were passaged to 6-well plates in a specific number of cells/well according to 
the experiments. After seeding the cells, culture media were supplemented with 50 μg/ml AA and 
10 mM β-GP for 10 days to induce the osteoblasts phenotype. Media were changed and 
supplemented every 3 days.  
 
4.4 ChemR23 expression in neonatal calvaria cultures  
To examine the expression of RvE1 receptor, chemR23, primary osteoblasts from neonatal 
calvaria cultures were obtained as described above. Calvaria osteoblasts were plated at a 
concentration of 105 cells/well in 6-well plates. After supplementation with AA and β-GP for 10 
days and confirming the osteoblast phenotype, cells were treated with IL-6/sIL-6R (10 ng/ml) with 
or without RvE1 (10 nM). RNA was isolated from 2- and 10-day old cultures using phenol-
chloroform method (TRIzol, Invitrogen). RNA concentration was measured by spectrophotometry 
(Nanodrop, Thermo Scientific). The RNA absorbance ratios of A260/A280 ~ 2.0 and A260/A230 
~ 1.8-2.0 were considered acceptable. Reverse transcription reaction was performed using 1 pg 
RNA using random hexamers, dNTP, buffer, nuclease-free water, ribonuclease (RNase) inhibitor 
and reverse transcriptase (High-Capacity cDNA Reverse Transcription Kit, ABI). The samples 
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were incubated in the GeneAmp PCR 9700 system (ABI): 25°C for 10 min, 37°C for 2 h, 85°C 
for 5 min with a total of 20 μl reaction volume. The cDNA products were stored at -20°C and 
diluted before the real time reaction. The expression of the murine chemR23 gene (Assay ID: 
Mm02619757_s1) in osteoblasts was measured with quantitative real-time PCR and analyzed 
using the ΔΔCt method. The final results were presented as relative quantification values (RQ=2-
ΔΔCt). A no-template control was used to detect contamination of the PCR reagents. The expression 
of target genes was calculated relative to GAPDH endogenous control and normalized to untreated 
controls at 2 days. 
 
4.5 Expression of chemR23 by immunohistochemistry  
In order to further evaluate the expression of chemR23, neonatal mouse calvaria were 
isolated as described before and fixed in 4% paraformaldehyde overnight. Calvaria were washed 
under running distilled water. Then, they were decalcified in 10% EDTA for 7 days. Next, calvaria 
were paraffin embedded and sectioned at 5 μm thickness sections which were stained with anti-
ChemR23, or isotype-matched non-specific antibody followed by incubation with the appropriate 
secondary antibody raised in rabbit and mounted with Vectashield containing DAPI. Slides were 
counterstained with H&E stain.  
 
4.6 Expression of osteoblast marker in neonatal calvaria osteoblast cultures  
In order to evaluate the expression of osteoblast markers, primary osteoblasts from neonatal 
calvaria cultures were obtained as described above. Calvaria osteoblast precursors were plated at 
a concentration of 105 cells/well in 6-well plates. After supplementation with AA and β-GP for 10 
days and confirming the osteoblast phenotype, cells were treated with IL-6/sIL-6R (10 ng/ml) with 
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or without RvE1 (10 nM). RNA was isolated from 2- and 10-day old cultures using the phenol-
chloroform method (TRIzol, Invitrogen). Reverse transcription reaction was performed using 1 pg 
RNA using random hexamers, dNTP, buffer, nuclease-free water, ribonuclease (RNase) inhibitor 
and reverse transcriptase (High-Capacity cDNA Reverse Transcription Kit, ABI). The samples 
were incubated in the GeneAmp PCR 9700 system (ABI): 25°C for 10 min, 37°C for 2 h, 85°C 
for 5 min with a total of 20 μl reaction volume. The cDNA products were stored at -20°C and 
diluted before the real time reaction. The expression of bone markers (Runx2, Osx, Ocn, Bsp, 
Col1a1, Alp, Opg, Rankl) was measured with quantitative real-time PCR and analyzed using the 
ΔΔCT method. The final results were presented as relative quantification values (RQ=2-ΔΔCt). A 
no-template control was used to detect contamination of the PCR reagents. The expression of was 
calculated relative to GAPDH endogenous control and normalized to untreated controls at 2 days. 
Assay IDs: Runx2 (Mm00501584_m1), Osx (Mm04209856_m1), Ocn 
(Mm03413826_mH), Bsp (Mm00492555_m1), Col1a1 (Mm00483888_m1), Alp 
(Mm00475834_m1), Opg (Mm00441906_m1), Rankl (Mm00441906_m1).   
 
4.7 Measurement of Osteoblast Proliferation by the BrdU incorporation assay  
To evaluate the proliferation of calvaria osteoblasts, neonatal mouse calvaria cells were 
obtained by sequential enzymatic digestion of calvariae as described above and plated at a 
concentration of 105 cells/well in 6-well plates. After supplementation with AA and β-GP for 10 
days and confirming the osteoblast phenotype, cells were treated with IL-6/sIL-6R (10 ng/ml) with 
or without RvE1 (10 nM) for 2 and 10 days. Bromodeoxyuridine (BrdU) (EMD Millipore) was 
incorporated into proliferating cells 24 hours prior to the end of the incubation period. Cells were 
fixed and DNA was denatured using the Fixing Solution. Wells were washed by wash buffer three 
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times. The anti-BrdU monoclonal was added and incubated for 1 hour at room temperature. The 
washing step was repeated. Then, the diluted goat anti-mouse IgG, peroxidase conjugate was 
added and the plate was incubated for 30 minutes at room temperature. After washing the plate, 
TMB peroxidase substrate was added and the plate was incubated for 30 minutes at room 
temperature in the dark. Positive wells were visible by a blue color, the intensity of which is 
proportional to the amount of BrdU incorporation in the proliferating cells. The reaction was 
stopped by adding the sulfuric acid solution into each well. The absorbance was read using a 
spectrophotometer microplate reader set at dual wavelength of 450/550 nm and the results were 
normalized to differentiated cells at 2 days (Spectramax 340PC 384 with a SoftMax Pro software 
4.3LS, Molecular Devices). 
 
4.8 Total protein concentration determination  
To measure protein concentration in cell lysates for alkaline phosphatase activity and 
Western blot experiments, Bicinchoninic acid assay (BCA) was used. A standard curve was 
prepared using serial dilutions of bovine serum albumin (BSA) at 0, 5, 25, 50, 125, and 250 μg/ml. 
200 μl BCA reagent (Pierce™ BCA Protein Assay Kit) were added to 10 μl sample and standards 
and assayed in duplicates. Absorbance was measured at 562 nm (Spectramax 340PC384 with 
SoftMax 4.3LS, Molecular Devices). Background absorbance of de-ionized water was subtracted 
from all measurements. Sample concentrations were extrapolated from the standard curve. 
 
4.9 Alkaline phosphatase activity  
To measure alkaline phosphatase activity in calvaria osteoblasts, cells were plated at a 
concentration of 105 cells/well in 6-well plates. After supplementation with AA and β-GP for 10 
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days and confirming the osteoblast phenotype, cells were treated with IL-6/sIL-6R (10 ng/ml) with 
or without RvE1 (10 nM). Cells were cultured in media supplemented with AA and BGP as 
described above for 14 days. Media was changed every 3 days. Cells were lysed with CelLytic M 
(Sigma Aldrich). Whole cell lysates were collected and assayed at 2, 7, 10, and 14 days. Cell 
lysates were incubated with p-nitrophenyl phosphate (pNPP) for 60 minutes at 25°C. The reaction 
was stopped using 0.5N sodium hydroxide. Optical density (OD) of the products at 405 nm was 
measured by spectrophotometry (Spectramax 340PC384 with SoftMax 4.3LS, Molecular 
Devices). Enzyme activity was calculated as the OD of the reaction product multiplied by the 
reaction volume and normalized to the reaction time and to the total protein.  
 
4.10 Alizarin red staining of the mineralized extracellular matrix  
In order to evaluate the formation of mineralized nodule formation, calvaria osteoblasts 
were plated at a concentration of 105 cells/well in 6-well plates. After supplementation with AA 
and β-GP for 10 days and confirming the osteoblast phenotype, cells were treated with IL-6/sIL-
6R (10 ng/ml) with or without RvE1 (10 nM). After incubation for 21 days, cells were fixed with 
4% formaldehyde in PBS, pH 7.4 for 10 min, and incubated with Alizarin Red dye for 20 min, 
after which the cells were washed, and images were acquired. Cells were incubated with 10% 
acetic acid for 30 minutes and collected heated at 85C for 10 minutes. After centrifugation, 
supernatant was collected and 10% ammonium hydroxide was added to neutralize the acid. The 
absorbance was read at 405 nm with a plate reader and the values were plot against a standard 
curve (Spectramax 340PC384 with SoftMax 4.3LS, Molecular Devices).  
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4.11 RANKL and OPG production  
To measure the production of OPG and RANKL in osteoblast cultures, neonatal mouse 
calvaria cell precursors were obtained by sequential enzymatic digestion of calvariae as described 
above and plated at a concentration of 105 cells/well in 6-well plates. After supplementation with 
AA and β-GP for 10 days and confirming the osteoblast phenotype, cells were treated with IL-
6/sIL-6R (10 ng/ml) with or without RvE1 (10 nM). Then, supernatants were collected after 2 and 
10 days of treatment, centrifuged at 4000 × g for 10 min at 4°C, and frozen at -80°C until assayed 
for the production of RANKL and OPG by ELISA.  
ELISA plates were coated with the OPG, RANKL (R&D Systems) capture antibodies 
overnight, then washed with 0.05% Tween® 20 in PBS, blocked using 1% BSA in PBS, and 
incubated with standards and samples. The detection antibody diluted in 1% BSA in PBS was 
applied to the plates, followed by Avidin-HRP in 1% BSA in PBS. The colorimetric signal 
developed after incubation with 1:1 mixture of H2O2 and Tetramethylbenzidine, and the reaction 
was stopped using 2N H2SO4. Absorbance was read at 450 nm (Spectramax 340PC 384 with a 
SoftMax Pro software 4.3LS, Molecular Devices), and the background absorbance values were 
subtracted. Sample concentration was calculated based on a standard curve. 
 
4.12 RvE1 signaling through ChemR23   
In order to examine the RvE1 signal transduction in osteoblasts, calvaria osteoblast were 
isolated as described above and seeded into 6-well plates at a density of 105 cells/well. Cells were 
cultured in media supplemented with AA and β-GP for 10 days. Then, osteoblasts were incubated 
for 30 min in the presence of IL-6/sIL-6R with or without RvE1. After the 30 min stimulation, 
cells were washed with ice-cold DPBS, and the appropriate volume of cell lysis reagent was added 
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supplemented with protease and phosphatase inhibitors. Proteins were prepared by mixing 5ug of 
lysate with 4x sample loading buffer with 2.5% volume β-ME. The lysates were denatured by 
heating to 95°C for 8 min. The proteins were separated by electrophoresis in 12% polyacrylamide 
gels in running buffer (25 mM Trizma base, 192 mM glycine, 0.1% sodium dodecyl sulfate (SDS)) 
at 100 V for 1.5 hours. Molecular weight standards were added in a separate well in the gel. A 
polyvinylidene difluoride (PVDF) membrane was prepared by 1 min incubation in methanol 
followed by 10 min incubation in blotting buffer (25 mM Trizma base, 192 mM glycine, 20% 79 
methanol). Proteins were transferred to the prepared PVDF membrane at 66 mA overnight at 4°C. 
The next day, the membrane was incubated in blocking solution (5% (w/v) BSA in 20 mM Tris-
HCI, 150 mM NaCl, 0.1% Tween-20 + 5% BSA (TBS-T)) for 1 h and then incubated with the 
targeted primary antibodies overnight at 4°C in 5% BSA in TBS-T on a shaker. The targets were 
explored using antibodies to phospho-S6 ribosomal protein (Ser235/236), S6 ribosomal protein, 
phospho-p70 S6 Kinase (Thr389), p70 S6 Kinase, phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204), p44/42 MAPK (ERK1/2), phospho-Akt (Ser473), AKT, phospho-mTOR (Ser2448), 
and mTOR (Cell Signaling Technology, Inc. Danvers, MA). The next day, the membrane was 
washed 3 times with TBS-T for 10 min and incubated with goat anti-rabbit IgG-horseradish 
peroxidase (HRP) secondary antibody (Cell Signaling Technology, Inc. Danvers, MA) in blocking 
solution (5% (w/v) milk in 20 mM Tris-HCI, 150 mM NaCl, 0.1% Tween-20 + 5% milk (TBS-T)) 
for 1 h at room temperature. The membrane was then washed 3 times for 10 min in TBS-T, and 
the HRP conjugate was detected using a chemiluminescence reaction. Then, an image was taken 
using chemiluminescence imaging system (G:Box, Syngene). Results of phosphorylated 
antibodies were normalized to the expression of β-actin and the total protein. To assay for 
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additional targets, the membrane was incubated for 20 min in a stripping buffer and washed 3 
times in TBS-T before incubation with the next primary antibody. 
Identified pathways were inhibited using specific pharmacological inhibitors to further 
validate those pathways. Wortmannin (1 μM) was used to inhibit the phosphorylation of Akt and 
downstream kinases, Rapamycin (10 nM) was used to inhibit the phosphorylation of mTOR as 
well as downstream kinases, and U0126 (10 μM) was used to inhibit the phosphorylation of 
ERK1/2. Cells were incubated with the inhibitors 1 hour before the treatment with RvE1. In order 
to confirm effective inhibition, cells were incubated with the inhibitors for 1 hour, then treated 
with RvE1 for 30 minutes. Total protein lysates were collected and Western blot analyses were 
performed to detect phosphorylation of AKT, ERK1/2, mTOR, p70 S kinase, and ribosomal S6 as 
described above. Once inhibition was confirmed, cells were incubated with inhibitors for 1 hour, 
then treated with RvE1 for 48 hours. The proliferation of cells was measured by BrdU assay and 
OPG production was measured by ELISA. 
In order to knockdown chemrR23, commercially available chemR23 siRNAs were used 
(siRNA IDs: MSS204833, MSS204834, MSS204835) and control siRNA (Cell Signaling 
Technology, Inc. Danvers, MA). Calvaria osteoblast were isolated as described above and seeded 
into 6-well plates at a density of 105 cells/well. Cells were cultured in media supplemented with 
AA and β-GP for 10 days. Then, according to the manufacturer’s recommendation, cells were 
transfected with a mixture of Lipofectamine TM 2000 and siRNA in Opti-MEMTM Reduced Serum 
Medium without antibiotics for 24 hours. Then, cells were treated RvE1 with or without IL-6/R 
for 48 hours. RNA was isolated for RT-qPCR to evaluate the efficiency of chemR23 knocking 
down. The supernatants were collected to assess the production of OPG; the cells were lysed for 
Western blot analyses to evaluate the expression of chemR23.   
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4.13 Statistical methods  
Experiments were performed in triplicates and repeated at least 3 times. Results were 
expressed as means ± standard error of the mean (SEM). When data were normally distributed, 
one-way analysis of variance (ANOVA) and Tukey HSD post hoc test for multiple comparisons 
were used for comparisons among three or more groups. If data were not normally distributed, 
Kruskal-wallis and Dunn’s post hoc tests were used.  An α-level of 0.05 was considered 
statistically significant. 
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5. Results 
5.1 Aim 1: Determine Resolvin E1 action in ligature-induced periodontitis in mice 
Rationale: Previous animal studies with experimentally induced periodontal disease 
models showed that RvE1 prevented leukocyte infiltration, significantly decreased osteoclast 
counts and stopped alveolar bone loss as well as restored lost periodontal tissue, including bone as 
confirmed with morphometric analysis and radiography. Histological analysis showed a reduced 
number of osteoclasts around the alveolar bone treated with RvE1. Soft tissue inflammation was 
also reduced in the gingiva of RvE1-treated animals.7,8,31,82,92,111 Moreover, periodontal 
regeneration that was observed in previous animal studies cannot be explained solely by inhibition 
of the osteoclast function and activity. Bone remodeling is characterized by the coupling between 
bone formation with osteoblasts and bone resorption by osteoclasts. There is limited information 
regarding the direct action of RvE1 on osteoblasts in periodontal bone regeneration. Our 
hypothesis was therefore, that RvE1 acts directly on osteoblast and promotes anabolic bone 
formation. A ligature-induced periodontal disease model was chosen to determine the impact of 
RvE1 on bone formation in experimental periodontitis in mice.  
Experimental design: Mice were anesthetized with Ketamine (100 mg/kg i.p.) and 
Xylazine (5 mg/kg, i.p.). A 7-0 silk suture was placed into the gingival sulcus of the maxillary 
right and left second molars and tied around the tooth with the knot being placed on the palatal 
side. The animals were divided into three groups; control (No ligature), ligature + vehicle, and 
ligature+RvE1. Animals received topical treatment with 10 μM RvE1 or vehicle based on their 
group assignment daily for 7 days. One week later, mice were sacrificed and the maxillae were 
divided into right and left halves. The left half was defleshed, cleaned and stained with methylene 
blue (1% in water) for bone loss measurements. The alveolar area bound by the cementoenamel 
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junction, the alveolar bone crest, mesial surface of the first molar, and the distal surface of the 
second molar was determined to assess alveolar bone loss using ImageJ software. 
Results: Placement of the ligatures around the 2nd molars induced periodontitis and caused 
significant alveolar bone loss as measured by the alveolar area bound by the cementoenamel 
junction, the alveolar bone crest, mesial surface of the first molar, and the distal surface of the 
second molar when compared to control mice with no ligation (P<0.001). Topical application of 
RvE1 resulted in a significantly less alveolar bone loss compared to ligated molars which were 
treated with vehicle (P<0.001) (Figure 6).  
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Figure 6: Resolvin E1 prevents ligature-induced periodontitis 
 
 
 
Figure 6: Resolvin E1 prevents ligature-induced periodontitis. A 7-0 silk suture was tied around 
the second maxillary molar to induce periodontitis. Molar ligation induced periodontal disease and 
caused significant alveolar bone loss in FVB mice when compared to control mice with no ligation. 
Topical application of RvE1 resulted in a significantly less alveolar bone loss compared to ligated 
molars which were treated with vehicle (Mean ± SD, *** P<0.001, ANOVA, n= 5 each group). 
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5.2 Aim 2: Determine the expression of the chemR23 in neonatal mouse calvaria 
osteoblasts. 
Rationale: RvE1 has specific binding sites on monocytes through the human chemokine-
like receptor 1 (chemR23). RvE1 may also interact with a minor receptor, BLT1, which is 
expressed on neutrophils and osteoclasts.31,111 ChemR23 expression was discovered on myeloid 
cells, however studies suggested that other cell types may also express the ChemR23.31,33 
ChemR23 is expressed in a variety of tissues, including the cardiovascular system, kidney, brain, 
and gastrointestinal tissues.7,46 Therefore, we determined the expression of chemR23 on 
osteoblasts to assess if RvE1 can have a direct impact on osteoblasts. Experiments were performed 
to validate and confirm that cells isolated from neonatal mice calvaria can express the osteoblast 
phenotype after stimulation with AA and β-GP. Osteoblast function was characterized by the 
expression of specific gene markers, such as Runx2, Osx, Ocn, Bsp, Alp and Col1a1. Since the 
expression of markers of osteoblast function and activity may be regulated by pro-inflammatory 
cytokines, we further examined the impact of RvE1 on osteoblast markers in an inflammatory 
environment. We also hypothesized that RvE1 will stimulate osteoblast proliferation and have a 
direct anabolic impact, which collectively will result in an increased bone formation. To test this 
hypothesis, we evaluated the proliferation of osteoblasts after the treatment with RvE1.   
Experimental design: To determine the expression of chemR23, primary osteoblasts were 
isolated from neonatal calvaria as described above. After supplementation with AA and β-GP for 
10 days, cells were treated with IL-6/sIL-6R (10 ng/ml) with or without RvE1 (10 nM). RNA was 
isolated from 2- and 10-day old cultures using phenol-chloroform method. Reverse transcription 
reaction was performed and the expression of the murine chemR23 gene in osteoblasts was 
measured with RT-qPCR.  Also, the expression of chemR23 was evaluated by 
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immunohistochemistry. Neonatal mouse calvaria were isolated as described before and fixed in 
4% paraformaldehyde overnight. Calvaria were paraffin embedded and sectioned at 5 μm 
thickness sections which were stained with anti-ChemR23, or isotype-matched non-specific 
antibody followed by incubation with the appropriate secondary antibody raised in rabbit and 
mounted with Vectashield containing DAPI. Slides were counterstained with H&E stain.  
To examine the phenotype of the cells, primary osteoblasts from neonatal calvaria cultures 
were obtained as described above. After supplementation with AA and β-GP for 10 days, cells 
were treated with IL-6/sIL-6R (10 ng/ml) with or without RvE1 (10 nM). RNA was isolated from 
2- and 10-day old cultures using the phenol-chloroform method. Reverse transcription reaction 
was performed and the expression of bone markers (Runx2, Osx, Ocn, Bsp, Col1a1, and Alp) was 
measured with RT-qPCR. Additionally, after supplementation with AA and β-GP for 10 days, cells 
were treated with IL-6/sIL-6R (10 ng/ml) with or without RvE1 (10 nM) for 14 days. Cells were 
lysed and the whole cell lysates were collected and assayed for alkaline phosphatase activity at 2, 
7, 10, and 14 days. Moreover, alizarin red staining of the mineralized extracellular matrix from 
calvaria osteoblasts was assessed after incubation for 21 days in the presence of media 
supplemented with AA and β-GP as described above with or without RvE1. Additionally, BrdU 
proliferation assay was performed to examine if RvE1 treatment has an impact on the proliferation 
of mouse calvaria osteoblasts. Neonatal mouse calvaria cells were obtained by sequential 
enzymatic digestion of calvaria as described above. Calvaria osteoblasts were plated at a 
concentration of 105 cells/well in 6-well plates. After supplementation with AA and β-GP for 10 
days and confirming the osteoblast phenotype, cells were treated with IL-6/sIL-6R (10 ng/ml) with 
or without RvE1 (10 nM) for 2 and 10 days. BrdU was incorporated into proliferating cells 24 
hours prior to the end of the incubation period. 
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Results: ChemR23 was expressed in calvaria osteoblasts in 2 and 10 day cultures. At 2 
days and 10 days, the expression was not significantly different between experimental conditions 
within each time point. However, the expression of chemR23 significantly increased in cells 
differentiated for 10 days compared to 2 days (P<0.005), in cultures treated with IL-6/sIL-6R 
(P<0.005), and RvE1 treated cells (P<0.05). (Figure 7). The expression of chemR23 as determined 
by immunohistochemistry from neonatal mice calvaria sagittal sections is shown in (Figure 8). 
Histological calvaria sections showed clearly that chemR23 is expressed in osteoblasts which 
indicate the potential of RvE1 direct actions on them.   
 The osteoblast phenotype of cells was confirmed by determining the expression of 
osteoblast markers (Runx2, Osx, Ocn, Bsp, Col1a1, Alp) by RT-qPCR. The expression of Runx2 
did not change between different conditions at 2 and 10 days (Figure 9). Osx expression was not 
changed among different conditions at 2 days. At 10 days, differentiated cells and RvE1 treated 
cells resulted in significantly increased expression of Osx compared to the control (P<0.05). 
Moreover, there was no significant change in the expression of Osx between 2 and 10 days (Figure 
10). When the expression of Ocn was evaluated, no significant change was observed among 
different conditions at 2 days. However, at 10 days, differentiated cells showed a significant 
increase in the expression of Ocn compared to the control (P<0.05). Additionally, RvE1 treated 
cells at 10 days resulted in a significant increase in the expression of Ocn compared to RvE1 treated 
cells at 2 days and the control at 10 days (P<0.005). Treating the cells with IL-6/sIL-6R at 10 days 
significantly decreased Ocn expression compared to RvE1 treated cells at 10 days (P<0.05) and 
RvE1 did not rescue the expression of Ocn at 10 days (P<0.05) (Figure 11). The expression of 
Bsp was not changed significantly between different conditions at 2 days. The expression of Bsp 
increased in cells supplemented with AA and β-GP compared to the control at 10 days (P<0.05) 
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as well as supplemented cells at 2 days (P<0.05). Also, supplemented cells increased the 
expression of Bsp significantly compared to the non-supplemented cells as well as cells treated 
with both RvE1 and IL-6/sIL-6R at 10 days (P<0.01) (Figure 12). The expression of Col1a1 was 
not significantly changed between different conditions at 2 and 10 days culture of primary 
osteoblasts (Figure 13). The expression of Alp was not changed significantly between different 
conditions at 2 days. Cells treated with RvE1 at 10 days showed a significant increase in the 
expression of Alp compared to the control (P<0.05) (Figure 14). Taken together, these results 
demonstrated that RvE1 did not impact the expression of Runx2, Osx, Ocn, Bsp and Col1a1 after 
2 and 10 days of treatment. However, RvE1 treatment resulted in a significant increase in Alp 
expression at 10 days.   
 The phenotype of osteoblasts was further examined by measuring the alkaline phosphatase 
activity. Treating cells with RvE1 resulted in a significant increase of alkaline phosphatase activity 
compared to cells supplemented with AA and β-GPas well as cells treated with IL-6/sIL-6R at 2 
and 7 days (P<0.005). The impact of RvE1 on the alkaline phosphatase activity in the presence of 
IL-6 was gradually decreasing over time and reached a comparable level to cells supplemented 
with AA and β-GP at 10 and 14 days (Figure 15). To further validate the phenotype of cells and 
evaluate the impact of RvE1 on osteoblast function, alizarin red staining was performed with and 
without the presence of RvE1 and IL-6/sIL-6. Results showed that primary mouse calvaria cells 
cultured in media supplemented with AA and β-GP secreted and mineralized ECM compared to 
non-supplemented cells (P<0.005), consistent of an osteoblast phenotype. RvE1 treated cells had 
significantly increased mineralization compared to the control as well as cells treated with IL-
6/sIL-6R (P<0.005) (Figure 16).  
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 The proliferation of mouse calvaria osteoblasts was measured with BrdU assay. At 2 days, 
cell proliferation was significantly increased after the treatment with RvE1 compared to 
undifferentiated and differentiated cells (P<0.05). Treating cells with IL-6/sIL-6R resulted in a 
significant reduction in proliferation compared to RvE1-treated cells (P<0.005) which was rescued 
by the treatment with RvE1 (P<0.05). At 10 days, in an inflammatory environment, RvE1 treated 
cells resulted in an increased proliferation compared to non-supplemented cells as well as to IL-
6/sIL-6R treated cells (P<0.05) (Figure 17).    
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Figure 7: Expression of ChemR23 in primary mouse calvaria osteoblasts 
 
 
 
Figure 7: ChemR23 mRNA was expressed in calvaria osteoblasts after 2 and 10 days of culture in 
media supplemented with AA and β-GP. Relative expression by RT-qPCR, relative to cells cultured 
in non-supplemented media at 2 days (set to 1). (Mean + SEM, n=4. ANOVA * P< 0.05, 
**P<0.005).  
ChemR23: Chemokine-like receptor-23. AA: Ascorbic Acid (50 μg/ml), β-GP: β-
Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: 
Resolvin E1 (10 nM) 
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Figure 8: ChemR23 immunostaining in calvaria osteoblasts. 
 
 
 
 
Figure 8: Sagittal sections of neonatal mouse calvaria showing the expression of chemR23 
evaluated by immunohistochemistry. Neonatal mouse calvaria were isolated and fixed in 4% 
paraformaldehyde overnight. Calvaria were paraffin embedded and sectioned at 5 μm thickness 
sections which were stained with anti-ChemR23, or isotype-matched non-specific antibody 
followed by incubation with the appropriate secondary antibody and mounted with Vectashield 
containing DAPI. Slides were counterstained with H&E stain. (A) Control (20X), (B) Control 
(40X), (C) ChemR23 staining (black arrows) (20x), (D) ChemR23 staining (black arrows) (40x). 
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Figure 9: Expression of Runx2 in primary mouse calvaria osteoblasts 
 
 
 
Figure 9: Runx2 mRNA was expressed in calvaria osteoblasts after 2 and 10 days of culture in 
media supplemented with AA and β-GP. Relative expression by RT-qPCR, relative to cells cultured 
in non-supplemented media at 2 days (set to 1). (Mean + SEM, n=3. ANOVA P>0.05).  
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 10: Expression of osterix in primary mouse calvaria osteoblasts 
 
 
 
Figure 10: Osterix mRNA was expressed in calvaria osteoblasts after 2 and 10 days of culture in 
media supplemented with AA and β-GP. Relative expression by RT-qPCR, relative to cells cultured 
in non-supplemented media at 2 days (set to 1). (Mean + SEM, n=3, ANOVA *P<0.05).  
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/s-IL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 11: Expression of osteocalcin in primary mouse calvaria osteoblasts 
 
 
 
Figure 11: Osteocalcin mRNA was expressed in calvaria osteoblasts after 2 and 10 days of culture 
in media supplemented with AA and β-GP. Relative expression by RT-qPCR, relative to cells 
cultured in non-supplemented media at 2 days (set to 1). (Mean + SEM, n=3. ANOVA *P<0.05, 
**P<0.005).  
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 12: Expression of bone sialoprotein in primary mouse calvaria osteoblasts 
 
 
 
 
Figure 12: Bone sialoprotein mRNA was expressed in calvaria osteoblasts after 2 and 10 days of 
culture in media supplemented with AA and β-GP. Relative expression by RT-qPCR, relative to 
cells cultured in non-supplemented media at 2 days (set to 1). (Mean + SEM, n=4. Kruskal-Wallis 
* P <0.05).  
BSP: Bone sialoprotein. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-
6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 13: Expression of type I collagen in primary mouse calvaria osteoblasts 
 
 
 
 
Figure 13: Type I collagen mRNA was expressed in calvaria osteoblasts after 2 and 10 days of 
culture in media supplemented with AA and β-GP. Relative expression by RT-qPCR, relative to 
cells cultured in non-supplemented media at 2 days (set to 1). (Mean + SEM, n=4. ANOVA 
P>0.05).  
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 14: Expression of alkaline phosphatase in primary mouse calvaria osteoblasts 
 
 
Figure 14: Alkaline phosphatase mRNA was expressed in calvaria osteoblasts after 2 and 10 days 
of culture in media supplemented with AA and β-GP. Relative expression by RT-qPCR, relative to 
cells cultured in non-supplemented media at 2 days (set to 1). (Mean + SEM, n=4. ANOVA 
*P<0.05).  
ALP: Alkaline phosphatase. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 
mM), IL-6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 15: Alkaline phosphatase activity 
 
 
 
 
 
Figure 15:  Alkaline phosphatase activity in calvaria osteoblasts cultured for 2, 7, 10 and 14 days. 
(Mean + SEM, n=3. ANOVA *P<0.05, *** P<0.005).  
ALP: Alkaline phosphatase. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 
mM), IL-6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
Figure 16: Alizarin red staining. 
  
 
 
 
 
Figure 16: Alizarin Red staining of mineralized nodules under osteogenic condition with or 
without resolving E1 for 21 days. (Mean + SEM, n=3. ANOVA *P<0.05, **P<0.005).  
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 17: BrdU proliferation assay 
 
 
 
 
Figure 17: BrdU proliferation assay for calvaria osteoblasts after 2 and 10 days of culture. Results 
were normalized to differentiated cells at 2 days (set to 1). (Mean + SEM, n=5. ANOVA *P<0.05, 
**P<0.005).  
BrdU: Bromodeoxyuridine. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 
mM), IL-6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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5.3 Aim 3: Determine the osteoblast function after RvE1 treatment.  
Rationale: Bone undergoes continuous remodeling through formation by osteoblasts and 
the resorption by osteoclasts via their cell-to-cell communication. TNF, RANKL, RANK and OPG 
play critical role in bone homeostasis.7 OPG, which is secreted by osteoblasts, acts as a decoy 
receptor in the RANKL–RANK signaling system. It results in inhibition of osteoclastogenesis as 
well as suppression of osteoclast survival. Therefore, OPG limits the number of mature osteoclasts 
and could have a determining effect on resorption rate and bone mass.46 In contrast, RANKL, 
which is a membrane-bound or secreted ligand by osteoblasts, acts as a stimulant for osteoclast 
differentiation and bone resorption via facilitating the fusion and differentiation of pre-osteoclasts 
into mature osteoclasts. We hypothesized that the anabolic impact of RvE1 on osteoblasts could 
be due to an increase in OPG/RANKL ratio, which favors bone regeneration and limits bone 
resorption. We further tested whether RvE1 increased OPG and decreased RANKL production by 
osteoblasts and examined the impact of RvE1 on their expression in osteoblasts.    
Experimental design: In order to determine the expression of Opg and Rankl, primary 
osteoblasts were isolated from neonatal calvaria as described above. After supplementation with 
AA and β-GP for 10 days, cells were treated with IL-6/sIL-6R (10 ng/ml) with or without RvE1 
(10 nM). RNA was isolated from 2- and 10-day old cultures using phenol-chloroform method 
(TRIzol, Invitrogen). Reverse transcription reaction was performed and the expression of Opg and 
Rankl mRNA in osteoblasts was measured with RT-qPCR and analyzed using the ΔΔCT method. 
The final results were presented as relative quantification values (RQ=2-ΔΔCt). The expression of 
was calculated relative to GAPDH endogenous control and normalized to untreated controls at 2 
days. To measure the production of OPG and RANKL, neonatal mouse calvaria cells were 
obtained by sequential enzymatic digestion of calvariae as described above. Calvaria osteoblasts 
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were plated at a concentration of 105 cells/well in 12-well plates. After supplementation with AA 
and β-GP for 10 days and confirming the osteoblast phenotype, cells were treated with IL-6/sIL-
6R (10 ng/ml) with or without RvE1 (10 nM). Then, supernatants were collected and assayed for 
the production of OPG and RANKL, 2 and 10 days after stimulation with IL-6/sIL-6R with and 
without RvE1 by ELISA.  
Results: The expression of Opg at 2 days did not change significantly among different 
conditions. At 10 days of treatment, RvE1 treatment resulted in a significantly increased 
expression of Opg compared to IL-6/sIL-6R treated cells (P<0.05) and that was maintained in the 
presence of IL-6 (P<0.005) (Figure 18). The Rankl expression was not changed significantly 
between conditions at 2 and 10 days of treatment (Figure 19). Opg/RanklmRNA expression ratio 
showed that it was not significantly changed at 2 days. However, RvE1 treated cells resulted in a 
significant increase in Opg/Rankl expression compared to the control at 10 days (P<0.005) and 
cells treated with IL-6/sIL-6R at 10 days (P<0.005) (Figure 20). Results from ELISA experiments 
showed that at 2 days, OPG production was significantly reduced by IL-6/sIL-6R compared to the 
control (P<0.005). However, RvE1 rescued that and brought the OPG level to a level comparable 
of the control (P<0.005). At 10 days, OPG secretion was not changed significantly between 
different conditions (Figure 21). The same supernatants were also analyzed for the production of 
RANKL by ELISA. At 2 days, IL-6/sIL-6R resulted in a significant increase in the production of 
RANKL compared to RvE1 treated cells (P<0.05). At 10 days, there was no significant change in 
the secretion of RANKL among different conditions (Figure 22). Therefore, the net result from 
OPG and RANKL production experiments was a significant increase in the OPG/RANKL 
production ratio at 2 days upon RvE1 stimulation compared to IL-6/sIL-6R (P<0.005), suggesting 
that RvE1 favors bone formation and limits bone resorption (Figure 23).  
69 
 
Figure 18: Expression of OPG in primary mouse calvaria osteoblasts 
 
 
 
Figure 18: OPG mRNA was expressed in calvaria osteoblasts after 2 and 10 days of culture in 
media supplemented with AA and β-GP. Relative expression by RT-qPCR, relative to cells cultured 
in non-supplemented media at 2 days (set to 1). (Mean + SEM, n=3, ANOVA, *P<0.05, ** P< 
0.005).  
OPG: Osteoprotegerin. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-
6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 19: Expression of RANKL in primary mouse calvaria osteoblasts 
 
 
 
 
Figure 19: RANKL mRNA was expressed in calvaria osteoblasts after 2 and 10 days of culture in 
media supplemented with AA and β-GP. Relative expression by RT-qPCR, relative to cells cultured 
in non-supplemented media at 2 days (set to 1). (Mean + SD, n=3). 
RANKL: Receptor Activator of Nuclear Factor Kappa-Β Ligand. AA: Ascorbic Acid (50 ug/ml), 
β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), 
RvE1: Resolvin E1 (10 nM) 
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Figure 20: OPG/RANKL relative expression ratio 
 
 
Figure 20:  OPG/RANKL relative expression ratio from calvaria osteoblasts cultured for 2 and 10 
days. Relative expression by RT-qPCR, relative to cells cultured in non-supplemented media at 2 
days (set to 1) (Mean + SEM, n=3, ANOVA **P<0.005).  
OPG: Osteoprotegerin. RANKL: receptor activator of nuclear factor-kappa-B ligand. AA: 
Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 + sIL-
6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 21: Osteoprotegerin (OPG) production 
 
 
Figure 21:  OPG production from calvaria osteoblasts cultured for 2 and 10 days. (Mean + SEM, 
n=4, ANOVA, *P<0.05, ** P<0.005).  
OPG: Osteoprotegerin. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-
6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 22: RANKL production 
 
 
 
Figure 22: RANKL production from calvaria osteoblasts cultured for 2 (Left side) and 10 days 
(Right side). (Mean + SEM, n=4. ANOVA *P<0.05).  
RANKL: receptor activator of nuclear factor-kappa-B ligand. AA: Ascorbic Acid (50 ug/ml), β-
GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), 
RvE1: Resolvin E1 (10 nM) 
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Figure 23: OPG/RANKL ratio 
 
 
 
Figure 23: OPG/RANKL ratio from calvaria osteoblasts cultured for 2 (Left side) and 10 (Right 
side) days. (Mean + SEM, n=5, ANOVA * P< 0.05).  
OPG: Osteoprotegerin. RANKL: receptor activator of nuclear factor-kappa-B ligand.  
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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5.4 Aim 4: Determine the signaling pathway(s) for osteoblast responses to RvE1. 
Rationale: As shown from the previous in vivo and in vitro experiments, RvE1 had a 
positive impact on mouse calvaria osteoblasts and resulted in favoring bone formation over bone 
resorption. So it was of interest to explore the mechanism of action of RvE1 on these cells. The 
MAPK pathway has an important function in osteoblast-specific gene expression by controlling  
RUNX2 which regulates expression of the Ocn gene and is essential for bone formation.191 AKT 
was also found to promote osteoblast differentiation and survival.241,242 Previous reports showed 
that RvE1 resulted in increased phosphorylation of ERK in HEK239 and monocytes.  Also, RvE1 
inhibited interstitial fibrosis in mouse obstructed kidney model through activation of the ERK and 
AKT signaling pathways, which are involved in cell proliferation.  Moreover, in chemR23-
transfected Chinese hamster ovary cells, chemR23 mediates RvE1 actions via AKT 
phosphorylation leading to phosphorylation of ribosomal protein S6.74,82,100,111 Therefore, we 
aimed to screen the previously discovered pathways for the RvE1 action through chemR23 in 
mouse calvaria osteoblasts.  
Experimental design: Calvaria osteoblasts were isolated as described above and seeded 
into 6-well plates at a density of 105 cells/well. Cells were cultured in media supplemented with 
AA and β-GP for 10 days. Then, calvaria osteoblasts were incubated for 30 min in the presence of 
IL-6/sIL-6R with or without RvE1. After the 30 minute stimulation, cells were lysed and RvE1 
signaling through ChemR23 was assessed using antibodies that identify phosphorylated substrates 
of AKT, MAP Kinases and downstream kinases for identification of substrates in osteoblasts after 
RvE1 stimulation with western blot. The targets were explored using antibodies to phospho-S6 
ribosomal protein (Ser235/236), S6 ribosomal protein, phospho-p70 S6 Kinase (Thr389), p70 S6 
Kinase, phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204), p44/42 MAPK (ERK1/2), phospho-
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Akt (Ser473), AKT, phospho-mTOR (Ser2448), and mTOR. Results of phosphorylated antibodies 
were normalized to the expression of β-actin and the total protein.   
Results: Relative quantification of the bands from western blot, normalized to β-actin and 
total protein showed a significant increase in the phosphorylation of rpS6 in response to RvE1 
compared to supplemented cells (P<0.05), cells treated with IL-6/sIL-6R (P<0.005), as well as in 
the inflammatory environment (P<0.05). Similarly, the phosphorylation of AKT was significantly 
increased after stimulating cells with RvE1 compared to the supplemented cells, IL-6/sIL-6R 
treatment, and that was maintained in the inflammatory environment (P<0.005). The 
phosphorylation of both mTOR and p70S6K was not significantly changed among the different 
conditions. The phosphorylation of ERK1/2 was significantly elevated after the stimulation with 
RvE1compared to the supplemented cells (P<0.005) (Figure 24).  
To further validate the RvE1 pathway in primary mouse calvaria osteoblasts, identified 
pathways were inhibited using specific pharmacological inhibitors. Wortmannin (1 μM) was used 
to inhibit the phosphorylation of AKT and downstream kinases, Rapamycin (10 nM) was used to 
inhibit the phosphorylation of mTOR as well as downstream kinases, and U0126 (10 μM) was 
used to inhibit the phosphorylation of ERK1/2. Cells were incubated with the inhibitors for 1 hour, 
then treated with RvE1 for 30 minutes. Total protein lysates were collected and western blot was 
performed to detect phosphorylation of ribosomal S6, ERK1/2, AKT, p70S6 kinase, and mTOR 
(Figures 25-29). Western blot results showed that the phosphorylation of ribosomal S6 and p70S6 
kinase were significantly inhibited with wortmannin, rapamycin, and U0126. Additionally, the 
phosphorylation of mTOR was significantly inhibited by wortmannin and rapamycin. 
Phosphorylation of AKT was significantly inhibited by wortmannin. Whereas ERK1/2 
phosphorylation was significantly inhibited with wortmannin and U0126. OPG production and 
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BrdU to examine the proliferation of cells were assessed. Results of OPG production showed that 
there was a significant reduction of RvE1-mediated OPG production with all the inhibitors 
(P<0.005) compared to OPG production without inhibitors (Figures 30-32). Also, proliferation 
experiments with pharmacological inhibitors showed that Wortmannin and U0126 significantly 
inhibited the proliferation in RvE1 treated cells compared to RvE1-treated cells without inhibitors 
(P<0.005). Only Wortmannin resulted in a significant proliferation inhibition of cells treated with 
RvE1 and IL-6/sIL-6R (P<0.05) (Figure 33). Taken together, these results indicated that AKT and 
ERK1/2 pathways are involved in the proliferation of osteoblasts. Also, it is indicated that AKT is 
an upstream regulator of other downstream pathways, such as ERK1/2.    
Using commercially available chemR23 siRNA, according to the manufacturer’s 
recommendation, cells were transfected with a mixture of Lipofectamine TM 2000 and siRNA in 
Opti-MEMTM Reduced Serum Medium without antibiotics for 24 hours. Then, cells were treated 
RvE1 with or without IL-6/R for 48 hours. RNA was isolated for RT-qPCR to evaluate the 
efficiency of chemR23 knocking down. The supernatants were collected to assess the production 
of OPG with ELISA. ChemR23 expression was significantly decreased compared to samples 
without siRNA or control siRNA, indicating an efficient knocking down of the receptor expression 
(Figure 34). Additionally, OPG production was significantly reduced with the knocking down of 
chemR23 compared to samples without siRNA or control siRNA (Figure 35).     
Based on the results from previous experiments, two signaling pathways may be activated 
in response to RvE1 when binding to chemR23 in mouse calvaria osteoblasts (Figure 36). The 
first one is through the phosphorylation of AKT through the activation of PI3K. As a result, AKT 
can activate mTOR that can induce the activation of p70S6 kinase and the subsequent 
phosphorylation of the S6 ribosomal protein. This pathway could explain the increase in OPG and 
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ALP production with subsequent increased bone formation and limiting bone resorption. The 
second pathway involves the increased phosphorylation of MAPK. That can be induced through 
three-part protein kinase cascade, consisting of a MAP kinase kinase kinase (MAPKKK or 
MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). MEK1 and 
MEK2 are the primary MAPKKs in this pathway which can activate p44 and p42 through 
phosphorylation of activation loop residues Thr202/Tyr204. This pathway could explain the increase 
in mouse calvaria osteoblast proliferation in response to RvE1 treatment. 
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Figure 24: Western blot of calvaria osteoblasts lysate stimulated with RvE1 with and without IL-6/sIL-6R for 30 minutes 
 
Figure 24: Representative image of western blot from calvaria osteoblast lysates. The targets were phospho-S6 ribosomal protein 
(Ser235/236), S6 ribosomal protein, phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), p44/42 MAPK (Erk1/2), phospho-p70 S6 
Kinase (Thr389), p70 S6 Kinase, phospho-AKT (Ser473), AKT, phospho-mTOR (Ser2448), and mTOR. Results were normalized to the 
expression of (β-actin) and to the total protein, relative to a supplemented cells (set to 1). (Mean + SEM, n=3, ANOVA * P< 0.05, 
**P<0.01). 
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), 
RvE1: Resolvin E1 (10 nM) for 30 minutes. 
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Figure 25: Inhibition of ribosomal S6 in calvaria osteoblasts lysate stimulated with RvE1 
with and without pharmacological inhibitors for 30 minutes 
 
Figure 25: Representative image of western blot from calvaria osteoblast lysates with or without 
pharmacological inhibitors. The targets were phospho-S6 ribosomal protein (Ser235/236), S6 
ribosomal protein. Results were normalized to the expression of β-actin and to the total protein, 
relative to a supplemented cells (set to 1). (Mean + SEM, n=3, ANOVA * P< 0.05, **P<0.01) 
compared to no inhibitors.  
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) for 30 minutes. 
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Figure 26: Inhibition of ERK1/2 in calvaria osteoblasts lysate stimulated with RvE1 with or 
without pharmacological inhibitors for 30 minutes 
 
Figure 26: Representative image of western blot from calvaria osteoblast lysates with or without 
pharmacological inhibitors. The targets were phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), 
p44/42 MAPK (Erk1/2). Results were normalized to the expression of β-actin and to the total 
protein, relative to a supplemented cells (set to 1). (Mean + SEM, n=3, ANOVA * P< 0.05, 
**P<0.01) compared to no inhibitors. 
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) for 30 minutes. 
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Figure 27: Inhibition of AKT in calvaria osteoblasts lysate stimulated with RvE1 with or 
without pharmacological inhibitors for 30 minutes 
 
Figure 27: Representative image of western blot from calvaria osteoblast lysates with or without 
pharmacological inhibitors. The targets were phospho-AKT (Ser473), Akt. Results were normalized 
to the expression of β-actin and to the total protein, relative to a supplemented cells (set to 1). 
(Mean + SEM, n=3, ANOVA * P< 0.05, **P<0.01) compared to no inhibitors. 
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) for 30 minutes. 
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Figure 28: Inhibition of p70 ribosomal S6 Kinase in calvaria osteoblasts lysate stimulated 
with RvE1 with or without pharmacological inhibitors for 30 minutes 
 
Figure 28: Representative image of western blot from calvaria osteoblast lysates with or without 
pharmacological inhibitors. The targets were phospho-p70 S6 Kinase (Thr389), p70 S6 Kinase. 
Results were normalized to the expression of β-actin and to the total protein, relative to a 
supplemented cells (set to 1). (Mean + SEM, n=3, ANOVA * P< 0.05, **P<0.01) compared to no 
inhibitors. 
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) for 30 minutes. 
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Figure 29: Inhibition of mTOR in calvaria osteoblasts lysate stimulated with RvE1 with or 
without pharmacological inhibitors for 30 minutes 
 
Figure 29: Representative image of western blot from calvaria osteoblast lysates with or without 
pharmacological inhibitors. The targets were phospho-mTOR (Ser2448), and mTOR. Results were 
normalized to the expression of β-actin and to the total protein, relative to a supplemented cells 
(set to 1). (Mean + SEM, n=3, ANOVA * P< 0.05, **P<0.01) compared to no inhibitors. 
AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-6/sIL-6R: Interleukin-6 
+ sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) for 30 minutes. 
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Figure 30: OPG production from calvaria osteoblasts cultured for 2 days with or without 
Rapamycin 
 
 
Figure 30: OPG production from calvaria osteoblasts cultured for 2 days with or without 
Rapamycin (10 nM). (Mean + SEM, n=4, ANOVA, ** P<0.005).  
OPG: Osteoprotegerin. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-
6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 31: OPG production from calvaria osteoblasts cultured for 2 days with or without 
U0126 
 
 
Figure 31: OPG production from calvaria osteoblasts cultured for 2 days with or without U0126 
(10 μM). (Mean + SEM, n=4, ANOVA, ** P<0.005).  
OPG: Osteoprotegerin. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-
6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 32: OPG production from calvaria osteoblasts cultured for 2 days with or without 
Wortmannin 
 
 
Figure 32: OPG production from calvaria osteoblasts cultured for 2 days with or without 
Wortmannin (1 μM). (Mean + SEM, n=4, ANOVA, ** P<0.005).  
OPG: Osteoprotegerin. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-
6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 33: BrdU proliferation assay for calvaria osteoblasts with and without 
pharmacological inhibitors 
 
 
Figure 33: BrdU proliferation assay for calvaria osteoblasts after 2 days of culture with and 
without pharmacological inhibitors. (Mean + SEM, n=3-5. ANOVA *P<0.05, **P<0.005).  
BrdU: Bromodeoxyuridine. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), 
IL-6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM), Wortmannin 
(1μM), U0126 (10μM). 
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Figure 34: ChemR23 mRNA expression in calvaria osteoblasts with and without ChemR23 
siRNA 
 
 
Figure 34: ChemR23 mRNA expression in calvaria osteoblasts after 2 days of culture in media 
supplemented with AA and β-GP with and without ChemR23 siRNA and control siRNA. Relative 
expression by RT-qPCR, compared to cells cultured in non-supplemented media (set to 1). (Mean 
+ SEM, n=3. ANOVA **P<0.005 compared to control).  
ChemR23: Chemokine-like receptor-23. AA: Ascorbic Acid (50 ug/ml), β-GP: β-
Glycerophosphate (10 mM). 
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Figure 35: OPG production from calvaria osteoblasts with or without chemR23 siRNA 
 
 
Figure 35: OPG production from calvaria osteoblasts cultured for 2 days with or without chemR23 
siRNA. (Mean + SEM, n=4, ANOVA ** P<0.005).  
OPG: Osteoprotegerin. AA: Ascorbic Acid (50 ug/ml), β-GP: β-Glycerophosphate (10 mM), IL-
6/sIL-6R: Interleukin-6 + sIL-6-receptor (10ng/ml), RvE1: Resolvin E1 (10 nM) 
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Figure 36: Hypothetical signaling pathways for RvE1 in mouse calvaria osteoblasts 
 
 
 
Figure 36: RvE1 binds to chemR23, which then can activate two pathways. The first one (left 
side) is through the phosphorylation of AKT through the activation of phosphoinositide 3-kinase 
(PI3K). As a result, AKT can activate mTOR that can induce the activation of p70 S6 kinase and 
the subsequent phosphorylation of the S6 ribosomal protein. This pathway correlates with an 
increase in translation of mRNA which can promote sustained cell growth and proliferation. The 
second pathway (right side) involves the increased phosphorylation of Mitogen-activated protein 
kinases (MAPKs). That can be induced through three-part protein kinase cascade, consisting of a 
MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), 
and a MAP kinase (MAPK). MEK1 and MEK2 are the primary MAPKKs in this pathway which 
can activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204. This 
pathway can be involved in different cellular activities, such as cell proliferation. 
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6. Discussion 
The objective of this project was to understand the mechanism of RvE1 actions on 
osteoblasts. Our hypothesis is that RvE1 acts directly on osteoblasts to promote bone formation 
and limits bone resorption via an increase in OPG/RANKL ratio, which in turn would limit 
osteoclast formation. In a ligature-induced periodontitis model in mice, topical application of 
RvE1 prevented the progression of periodontal bone loss compared to vehicle treatment. Our 
results confirmed that murine calvaria osteoblasts express ChemR23, which indicated a potentially 
direct action of RvE1 on osteoblasts. The expression of osteoblast gene markers (Runx2, Osx, 
Col1a1, Bsp and Ocn) was not significantly altered by RvE1 in an inflammatory milieu. However, 
RvE1 treatment significantly increased ALP activity after 2 and 7 days in mouse calvaria 
osteoblast cultures. RvE1 enhanced in vitro mineralization as well as osteoblast proliferation. A 
key finding of this study was that RvE1 treatment reversed the IL-6-mediated inhibition of OPG 
production by osteoblasts and significantly inhibited RANKL production resulting in an increase 
in OPG/RANKL ratio. These actions by RvE1 were mediated via an increased phosphorylation of 
rS6 kinase, ERK 1/2 and AKT pathways. Taken together, these results explained the mechanism 
of osteogenic impact of topical RvE1 treatment in periodontal bone regeneration.  
The etiology of periodontitis is bacterial plaque which initiates an inflammatory response 
that leads to periodontal tissue destruction including connective tissue and bone.8,243 Inflammatory 
lipid mediators, such as PGE1 and LTB4, play an important role throughout the pathogenesis of 
periodontitis and its progression to the chronic lesion.8,244,245 Recruitment of monocytes to the 
chronic lesion enhances the inflammatory response with subsequent secretion of inflammatory 
cytokines, such as IL-1β, TNF-α, IL-6 and others. The ultimate goal in the treatment of 
periodontitis is to have a complete tissue regeneration. However, that is not always successful in 
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all the cases. Regenerative and therapeutic strategies involve adding growth factors, substrates, 
and other molecules to mimic development. Failure to resolve the inflammation could be the 
missing link in these strategies which may lead to the failure of therapy. Resolution of 
inflammation involves returning to the tissue homeostasis. The physiologic resolution of an 
inflammatory response is essential to maintain homeostasis which generates specific mediators 
that can inhibit the leukocyte infiltrate during inflammation and promote resolution.8,36,41 These 
chemical mediators are EPA-derived and endogenously-generated in inflammatory exudates 
collected during the resolution phase. They were termed resolvins because specific members of 
the family control the magnitude and duration of inflammation in animal models.8,15,41,74,80 
Previous reports showed that these pro-resolving mediators inhibit neutrophil infiltration, increase 
apoptosis of neutrophils and promote resolution.8,30,80,106 RvE1 specifically interacts with the 
LTB4 receptor BLT1 on neutrophils and ChemR23 on monocytes to regulate leukocytes during 
inflammation.8,80 However, the direct impact of RvE1 and other SPMs on bone cells is not known. 
The results from the present study demonstrated the role of local inflammation in bone 
regeneration; that RvE1 acted as a promotor for tissue regeneration and bone formation.  
Our results showed that the topical application of RvE1 prevented the progression of 
ligature-induced periodontitis in mice compared to the vehicle treatment similar to the in vivo 
impact of RvE1 treatment observed in previous studies. In a study by Hasturk et al,15 the actions 
of RvE1 in rabbit periodontitis initiated by Porphyromonas gingivalis (P.g.) was evaluated. 
Periodontitis was induced by ligating lower second premolars with 5-0 silk sutures with topical 
application of P.g. to the ligature 3 times per week. RvE1 was applied topically to the ligature in 
a 1 μg/ml PBS solution containing 5% ethanol (4 μl per application) from baseline for 6 weeks; 
controls received the PBS vehicle alone. Other groups were included that received ligature, but no 
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P.g.; and another group neither ligature nor microbial challenge. The results showed that topical 
application of RvE1 three times per week at the ligature site inhibited bone and tissue destruction 
by >95%. Additionally, histological sections showed that animals treated with RvE1 exhibited no 
neutrophils in the periodontal tissues with no osteoclast-like cells in the bone. These results 
indicated that RvE1 could be an effective way to prevent periodontitis and confirmed the 
inflammatory involvement in the pathogenesis of periodontitis. That was demonstrated with the 
control of inflammation with RvE1 which leads to clearance of the infection.15 Moreover, the 
potential of RvE1 for treating established periodontitis was established in the same rabbit model 
of ligature and P.g. induced periodontitis in another study by Hasturk et al.8 In this study, the 
disease was established for 6 weeks in all animals. Then, P.g. application was stopped and the 
remaining animals were treated with RvE1 or vehicle for an additional six weeks. The results 
demonstrated that topical RvE1 treatment did not only inhibit disease progression but it resulted 
in regeneration of lost periodontal tissues, including bone and connective tissue attachment of the 
tooth to the bone.8 Other studies showed similar positive impact of RvE1 on bone regeneration in 
other models, such as cranial defect. In a study by Gao et al, a 1mm craniotomy defect was created 
in the parietal bone through a scalp incision using a round carbide bur. RvE1 (100ng in 20 μl PBS) 
or vehicle was injected subcutaneously over the defect every 2 days for 14 days. Results 
demonstrated that there was a significant increase in new bone formation with RvE1 treatment in 
wild type mice which was confirmed histologically.82 One point worth mentioning when 
comparing results from our study to previous in vivo periodontitis models and RvE1 treatment is 
the absence of complete regeneration of lost periodontal tissues in our mouse model. That may be 
explained by the difference in mice oral microflora, due to their dietary habits, compared to other 
animals. Also, in our model, the ligature was not removed while in rabbit studies, P.g. application 
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was stopped. This could also lead to variation in oral microflora with subsequent differences in 
response to treatment. Evidence from our study and previous reports indicate that resolving 
inflammation and return tissues to homeostasis require the active removal of immune and 
inflammatory cells from the lesion.23,41 These principles may be applicable to other inflammatory 
diseases including arthritis.15,246 These observations provide a potential of RvE1 in controlling 
inflammation and promoting regeneration of lost tissues, including connective tissue and 
bone.15,247 
The next in vitro experiments were focused on the direct actions of RvE1 on osteoblasts. 
Neonatal mouse calvaria were used as a source of primary osteoblasts. Utilizing primary cells 
reflect the in vivo model and therefore, have more preclinical and clinical applicability. However, 
species and genomic differences make it difficult to extrapolate results to human disease and 
treatment outcomes. Furthermore, in animals, the biology and structure of bone is different from 
humans due to the differences in size and weight which may influence bone composition, quality, 
remodeling, healing and signaling pathways. Nevertheless, isolating primary cells from animals 
has the advantage of easily obtaining them from different parts of the skeleton. Also, animal 
selection will be more controlled in term of age, weight and gender.120 Moreover, primary calvaria 
osteoblast cultures allow quantitative studies of the main functions of osteoblasts, bone matrix 
deposition and mineralization. Also, osteoblasts can be studied at different stages of differentiation 
from the early immature, proliferating cells to the mature bone-forming osteoblasts at a later stage 
of cultures.248 Although mouse calvaria model is not a true periodontal system, it can be utilized 
in a variety of disease applications relevant to dental research. It is useful in studying bone 
remodeling and the impact of inflammation, destruction and repair relevant to larger animal 
models.249 
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Two RvE1 receptors were identified, chemR23 and BLT-1. ChemR23, was identified on 
monocytes and other tissues, such as renal, cerebral, gastrointestinal, bone marrow, cardiovascular 
tissues, and developing bone tissues.80,82,83,91,250 Its inhibition of TNF-α stimulated NFκB 
activation seems to be directly related to its ability to specifically bind RvE1.74,250 BLT-1 was 
identified on neutrophils and osteoclasts. The impact of RvE1 on osteoclasts via signaling through 
BLT-1 was studied previously. However, how RvE1 directly impacts bone cells is still poorly 
understood. The expression of chemR23 in developing bone tissue and osteoblasts indicate a role 
in bone formation.82,84,250 Our results confirmed the expression of chemR23 in murine calvaria 
osteoblasts at the mRNA level and immunohistochemistry. Also, there was no significant 
differences in the expression of chemR23 after treatment with RvE1 with and without pro-
inflammatory stimulation with IL-6/sIL-6R. To our knowledge, there were no previous studies 
evaluated the impact of inflammatory milieu and RvE1 treatment on the expression of chemR23 
in primary osteoblasts. However, a report evaluating the functional interactions between RvE1 and 
ChemR23 showed that TNF-α and interferon-γ (IFN-γ) up-regulate monocyte ChemR23 and 
COX-2 transcripts.74,82   
As RvE1 prevented the progression of ligature-induced periodontitis in mice and its 
receptor was expressed in osteoblasts, we wanted to examine if RvE1 directly acts on osteoblasts 
to stimulate bone formation in vitro. The osteogenic potential of RvE1 was examined in a mouse 
calvaria osteoblast that upon differentiation produces extracellular collagen matrix, calcification 
nodules and express osteoblast markers such as Runx2, Osx, Col1a1, Alp, Bsp and Ocn.82,251 Our 
results demonstrated that RvE1 did not significantly change the expression of Runx2 or  type 1 
collagen at 2 and 10 days of treatment. However, RvE1 treatment by itself resulted in a significant 
increase in the expression of Ocn and Osx at 10 days of treatment compared to the control. 
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Nevertheless, the increased expression of Ocn was reversed by stimulation with IL-6/sIL-6R. 
Moreover, RvE1 treatment at 10 days resulted in a significant decrease in the expression of Bsp 
compared to the differentiated cells. On the other hand, RvE1 treatment at 10 days increased the 
expression of Alp in the presence of IL-6 compared to the control. Furthermore, RvE1 treatment 
resulted in a significant increase in ALP activity after 2 and 7 days of treatment compared to other 
conditions. However, that significant increase in ALP activity disappeared at 10 and 14 days of 
culture. That could be explained due to the fact that ALP activity in primary mouse calvaria 
osteoblasts peaked at a later stage of differentiation, around day 10 and 14 in culture.163 Another 
aspect that we wanted to examine was the impact of RvE1 treatment on the in vitro mineralization 
and osteoblast proliferation. Our results indicate that RvE1 treatment of osteoblasts for 21 days 
resulted in a significant increase in mineralization, measured by alizarin red staining. RvE1 
treatment for 2 and 10 days, resulted in a significant increase in the proliferation of cells compared 
to the control. Enhancement of progenitor cell proliferation followed by differentiation may 
explain the increase in ALP activity and mineralization. In another study, results showed that RvE1 
did not significantly change osteoblast differentiation markers Alp, Bsp and RunX2 in calvaria 
osteoblasts, arguing against a direct action of RvE1 on bone formation.82 Indeed, although in a 
different cell type, another study evaluated the impact of knockdown of chemR23 expression prior 
to adipogenic differentiation of bone marrow stem cells. Their results showed that knockdown 
chemR23 resulted in a 2.5- to 5-fold increase of the mRNA levels of the osteoblast markers Alp, 
Col1a1, and Osx compared with vehicle-treated controls. Moreover, there was a consistent finding 
which was an increase in the mineralization when chemR23 knockdown was performed prior to 
differentiation.83 Taken together, these results indicate that RvE1 may act on chemR23 receptors 
on osteoblasts; however, its main action could be different from osteoblast differentiation. RvE1 
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actions on osteoblasts may be boosting ALP activity at an early stages, enhancing mineralization, 
and increasing the proliferation of osteoblasts. Combining results from the present study with 
previous reports about RvE1 actions on osteoclasts, enable us to have a better understanding of the 
positive in vivo impact of RvE1 on bone regeneration in periodontitis models in animals.      
In inflammatory diseases, including periodontitis, the RANKL/OPG ratio is consistently 
elevated. In periodontitis, increased RANKL/OPG ratio may indicate that bone resorption is still 
active which means that the corresponding sites are at a potential risk of further periodontal 
breakdown at a future time-point. This emphasizes the need for immune-modulation therapies 
targeting the RANKL-OPG-specific host responses in the long-term management of 
periodontitis.115,221,250,252 RANKL acts as the primary signal for osteoclast differentiation, while 
OPG acts as a decoy receptor that inhibits RANKL–RANK binding and thus inhibits 
osteoclastogenesis. Therefore, the RANKL/OPG ratio is the considered the major driver for 
osteoclastogenesis.250 To examine if RvE1 has a direct action on osteoblasts to regulate 
OPG/RANKL ratio, murine calvaria osteoblasts were isolated from wild type neonatal mice. These 
cells, in response to inflammation, have been shown to stimulate the release of RANKL and inhibit 
secretion of OPG, which will result in bone resorption.250,253,254 A potential mechanism of the 
direct action of RvE1 on osteoblasts is suggested by in vitro experiments. In our study, RvE1 
rescued IL-6-mediated inhibition of OPG production by murine calvaria osteoblasts. Also, RvE1 
treatment resulted in a significant reduction of RANKL production by osteoblasts. The net result 
was an increase in OPG/RANKL ratio favoring bone formation and limiting bone resorption, thus 
supporting net bone formation in the bone remodeling cycle. Our results are in agreement with 
previous report by Elkholy et al. Results from that study showed that RANKL production by 
murine calvaria osteoblasts stimulated by IL-6 was significantly reduced by RvE1 treatment at 100 
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nM. However, RvE1 had no statistically significant impact on OPG production which is in contrast 
to our results in the present study. Nevertheless, evaluating the RANKL/OPG ratio showed that 
treatment with RvE1 at 100 nM resulted in a significant reduction in the RANKL/OPG ratio which 
is similar to our results. The results indicated that RvE1 suppresses levels of RANKL through a 
direct action on osteoblasts leading to a shift in the OPG/RANKL ratio. Similarly, in another study 
by Gao et al, expression of RANKL and OPG were measured in neonatal calvaria osteoblasts 
stimulated with the IL-6 and sIL-6R for 48 hours. Results from that study showed that, in contrast 
to our study, RANKL expression was not significantly changed by RvE1. However, in agreement 
with our results, RvE1 (1–100nM) rescued OPG expression that was decreased by IL-6/sIL-6R. 
Similar to our results, the overall impact of RvE1 on osteoblasts was an increase in OPG/RANKL 
ratio.82 Our results confirmed findings from previous reports that RvE1 decreases the 
RANKL/OPG ratio to favor bone preservation and limit osteoclast maturation and bone resorption. 
It would be of an interest to examine histological sections from the in vivo part of this study to 
evaluate whether the same in vitro impact of RvE1 is present in mice periodontal tissues.   
Our results showed a positive impact of topical RvE1 treatment in vivo via preventing the 
progression of ligature-induced periodontitis. Also, murine calvaria osteoblasts expressed 
chemR23 and demonstrated an osteoblast phenotype which was confirmed with ALP activity and 
in vitro mineralization. Actions of RvE1 on osteoblasts included an enhancement of osteoblast 
proliferation and an increase in OPG/RANKL ratio promoting bone formation and limiting bone 
resorption. The next experiments were focused on understanding the mechanism by which RvE1 
exerts its actions on osteoblasts.  
To our knowledge, no studies examined the signaling pathways of RvE1 actions on 
osteoblasts before. However, RvE1-mediated actions via chemR23 in other cell types were tested 
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by several authors. Previous reports showed that RvE1 activated AKT and MAPK pathways in 
leukocytes.74 Also, in another study, RvE1 treatment of IL-6-stimulated osteoblasts revealed that 
the PI3K–AKT pathway showed a significant perturbation. RvE1 was shown to act on multiple 
upstream and downstream targets of AKT impacting a variety of cell functions, such as 
differentiation, protein synthesis, and apoptosis. These interactions also influenced the NFκB, 
MAPK, and p53 signaling pathways.250 Moreover, a previous report showed that stimulation of 
human ChemR23-transfected CHO cells and human macrophages transduce chemR23 signals 
through the Akt/rS6/mTOR pathway.111 Another study showed that RvE1-stimulated neutrophils 
demonstrated an increase in the intracellular rS6 signaling compared to baseline controls. 
Additionally, RvE1 treatment significantly increased rS6 phosphorylation in both type-2 diabetic 
and healthy neutrophils.3 In agreement with previous studies, our results in the present study 
revealed that RvE1 treatment resulted in an increased phosphorylation of AKT, MAPK and 
ribosomal S6 (rS6) pathways. AKT-PI3K pathway is involved in cell survival and inhibiting 
apoptosis.255 Also, AKT was established as an important regulator of both osteoblasts and 
osteoclasts by promoting their differentiation and survival to maintain bone mass and turnover.242  
rS6 is known to regulate production of ribosomal proteins and elongation factors necessary for 
translation.256,257 rpS6 has been shown to be directly involved, through its phosphorylation, in 
controlling cell size (540). In MC3T3 cells, rpS6 is expressed during the proliferation period and 
decreases after day 10 of differentiation.188 Furthermore, mTOR acts as a nutrient and mitogen 
sensor to positively regulate translation and ribosome biogenesis.111 Upon activation, mTOR 
phosphorylates two key translational regulators: p70S6K and 4E-BP1. p70S6K activation leads to 
the phosphorylation of rS6.111,258 Regulation of translation and the control of ribosome biogenesis 
are essential for cell growth and proliferation. MAPK is known to be involved in proliferation of 
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cells. Three MAPK families have been identified in mammalian cells; classical MAPK (also 
known as ERK), C-Jun N-terminal kinase/ stress activated protein kinase (JNK/SAPK) and p38 
kinase. MAPK pathways evoke an appropriate physiological response including cellular 
proliferation, differentiation, development, inflammatory responses and apoptosis in mammalian 
cells. GPCRs can also lead to activation of MAPKs mediated by stimulation of a large number of 
complex cascades. The classical ERK family (p42/44 MAPK) is known to be an intracellular 
checkpoint for cellular mitogenesis. In cultured cell lines, mitogenic stimulation by growth factors 
correlated with stimulation of p42/44 MAP kinase. Interfering with components of the ERK 
signaling pathway results in a significant inhibition of cell proliferation. Conversely, stimulating 
ERK1 activity results in enhanced cell proliferation.259 To further validate the specificity of these 
identified pathways to RvE1 actions on osteoblasts, specific pharmacological inhibitors were used. 
After confirming a successful inhibition, there was a significant inhibition of RvE1-mediated OPG 
production and osteoblast proliferation. These data suggest that the actions of RvE1 on osteoblasts 
are mediated through these pathways; Akt, MAPK and rpS6.. Whereas, the enhanced proliferation 
could be mediated via phosphorylation of Akt and MAPK pathways.  
While our results are exciting from the perspective of the direct actions of RvE1 on 
osteoblasts, there are some limitations and several questions that need to be answered in future 
studies. Utilizing neonatal mouse calvaria osteoblasts might not be an accurate representation of 
the periodontal tissues. Differences between osteoblasts isolated from calvaria or periodontium 
should be investigated. Also, to have more physiologic bone environment in vitro, co-culture of 
osteoblasts and osteoclasts could be utilized to examine the RvE1 actions on bone. Moreover, with 
recent advancements in cultures, three-dimensional ex vivo bone model may be a good model to 
study the impact of RvE1 on bone metabolism. RvE1 binds to two different receptors, chemR23 
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and BLT-1. It is of interest to investigate the expression of BLT-1 in osteoblasts and determine if 
RvE1 exerts any actions on osteoblasts via BLT-1 that are different from RvE1-chemR23 
interaction. Additionally, it is still unclear how RvE1 rescues IL-6-mediated inhibition of OPG 
and how RvE1 inhibits RANKL production by osteoblasts. As RvE1 phosphorylates rS6 which is 
involved in increased protein synthesis, how was RANKL production inhibited with RvE1? 
Investigation of the IL-6 signaling pathway in osteoblasts leading to regulation of OPG and 
RANKL secretion and how rS6 phosphorylation acts on this pathway is necessary. Furthermore, 
RvE1 is a single pro-resolving mediator among others, such as lipoxins and maresins. Investigating 
the impact of other inflammation resolution mediators, either individually or in combination, on 
bone regeneration is of interest.  
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7. Conclusion and summary 
The goal of our project was to investigate the RvE1 mechanism of action on osteoblasts. 
Our in vivo experiments showed that topical application of RvE1 prevented the progression of 
ligature-induced periodontitis in mice. This experiment supports our hypothesis that RvE1 can 
directly act on osteoblasts as bone remodeling involve both osteoblasts and osteoclasts. IL-6 is a 
cytokine that causes osteoclast differentiation directly and indirectly through osteoblasts. RvE1 
receptor, chemR23, is a GPCR receptor known to mediate RvE1 actions and we showed that it is 
expressed in murine calvaria osteoblasts. Also, our results indicate that RvE1 did not impact the 
expression of osteoblast gene markers. However, RvE1 treatment resulted in an increase in ALP 
activity and enhancement of in vitro mineralization in neonatal mouse calvaria osteoblasts. In 
addition, the proliferation of murine calvaria osteoblasts was enhanced by RvE1 treatment. We 
showed that RvE1 rescued IL-6-induced inhibition of OPG production and inhibited RANKL 
secretion in murine calvaria osteoblast culture. The net results was a significant increase in 
OPG/RANKL ratio which favors bone formation and decreases osteoclast differentiation and bone 
resorption. In conclusion, our experiments indicated that RvE1 could be beneficial in bone 
remodeling via a direct action on osteoblasts. RvE1 has a potential to be used as a treatment 
strategy especially in inflammatory diseases of bone, such as osteoporosis, arthritis and periodontal 
diseases. 
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